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Abstract
A patient’s health is reflected in multiple longitudinal biomarkers in many
chronic diseases. To treat a patient, physicians need to integrate information
across multiple parameters and organ systems, factoring in the patient’s prior
trajectory and baseline risk factors to estimate his/her current and future
health state depending on treatments. Aggregating this complex, longitudinal
data for clinical use requires a major time investment on the part of the treating
physician when time with patients is short. It is also challenging to clearly
explain this information to patients during a routine clinical visit to facilitate
shared decision making.
In this thesis, we introduce a statistical framework and a set of data science
tools we developed to facilitate and improve clinical care in information
rich settings. Motivated by a case study of scleroderma, a complicated and
heterogeneous disease that affects multiple organ systems, we build methods
to help understand each individual’s disease progression throughout time in
multiple dimensions.
Modeling trajectories in multiple dimensions involves a choice of whether
to jointly model all markers in a single model or to model each marker sepa-
rately. We investigate the advantages and disadvantages of jointly modeling
iv
the outcome variables instead of using separated models when both address
the main scientific or clinical question. We present general formulae for the
relative efficiency of the two model estimators and examine in detail the
implications of these formulae on the scleroderma clinical data.
Then, we extend the framework developed to estimate individual trajec-
tory to predicting patients’ risk of having clinically defined critical events in
the near future. We introduce a cross-validated sequential prediction (CVSP)
algorithm that quantifies patients’ risk of multiple important clinical events by
predicting their future trajectories given the prior trajectory in multidimension
and baseline risk factors.
Finally, we construct a web-based application that shows a patient’s lon-
gitudinal data in multiple organ systems visualized against those of other
similar patients in selected clinical subgroups. To improve patient care in
clinical settings, we introduce our approach of implementing and testing the
utility of the interactive interface to communicate visualizations of a patient’s
and reference population’s longitudinal data.
v
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We live in an era marked by a plethora of data. Modern technologies in
biology, information, and communication combined with recent scientific dis-
coveries has generated vast amounts of novel data that relates to quantifying
an individual’s health including, for example, step counts, vital signs, and
DNA sequences. In clinic, it is typical that the disease of interest is monitored
using many biomarkers. Longitudinal clinical measures and occurrences of
clinical events throughout a patient’s course of disease represent opportunities
to practice evidence-based clinical care but also pose significant challenges.
Physicians need to integrate information across multiple parameters and or-
gan systems, factoring in a patient’s prior trajectory and baseline risk factors
to estimate his/her current and future health state depending on treatments.
Aggregating this complex, longitudinal data for clinical use requires a major
time investment on the part of the treating physician when time with patients
is short. It is also challenging to clearly explain this information to patients
during a routine clinical visit to facilitate shared decision making.
This thesis introduces a statistical framework and a set of data science
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tools we developed to facilitate and improve clinical care in information
rich settings. Motivated by a case study of scleroderma, a complicated and
heterogeneous disease that affects multiple organ systems, we build methods
to help understand each individual’s disease progression throughout time
in multiple dimensions. The Johns Hopkins Scleroderma Center dataset
has characteristics that are common in many problems where the individual
unit’s trajectory is the focus. We observe a mix of continuous measures
and discrete events at irregularly observed times. Of the five continuous
outcomes of interest, some clearly follow non-Gaussian distributions with
means and variances depending upon predictor variables. We also have
multiple predictors clinically known to influence the outcomes that need
to be considered. In this thesis, we focus on building models that flexibly
describe the population and individual’s trajectories that can accommodate
the heterogeneity of measures, observations and individuals.
Modeling trajectories in multiple dimensions involves a choice of whether
to jointly model all markers in a single model or to model each marker sepa-
rately. Either approach can be used to answer questions about within-measure
contrasts, but the marker-specific models are not sufficient to answer contrasts
across multiple measures. Because the joint model quantifies the covariation
across measures, it can produce more valid estimates and inferences about
cross-measure contrasts.
In problems of the first kind, when a "separated" set of models, fit one
at a time, addresses the same question as a joint or "combined" model, the
question remains: what are the relative merits of each approach? Separated
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models are simpler to specify and fit because each measure can be handled in
a univariate regression using standard software for model fitting, checking,
and inferences. But using separated models implicitly assumes there is no
correlation among the multiple measures at the same or different times. As
discussed in the thesis, this assumption, when wrong, will result in a loss of
efficiency.
In Chapter 2 of this thesis, we investigate the advantages and disadvan-
tages of jointly modeling covariates instead of using separated models when
both address the main scientific or clinical question. We present general for-
mulae for the relative efficiency of the two model estimators and examine
in detail the implications of these formulae on the motivating scleroderma
clinical data. Our approach is somewhat unique in that we focus on relative
performance of the two models on individual patient trajectories rather than
the average trajectories for subpopulations.
The framework developed to estimate individual trajectory by jointly
modeling multiple markers can be extended to predicting patients’ risk of
having critical events in the near future. For clinical care of many chronic
diseases, it is often of importance to generate real-time, actionable predictions
for sentinel events. For scleroderma patients, cardiomyopathy, pulmonary
arterial hypertension (PAH), and interstitial lung disease (ILD) can result
in significant morbidity and mortality, and early detection and therapy can
improve clinical outcomes. Timely risk predictions are essential because
they: (1) warn clinicians of higher risk in need of increased monitoring and
interventions; (2) reduce concerns in patients at lower risk. Increased concern
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for these events are defined by clinicians to be the crossing of biomarker
thresholds. In chapter 3, we introduce a prediction algorithm that quantifies
patients’ risk of multiple important clinical events by predicting their future
trajectories given the prior trajectory and baseline risk factors. The models
used in prediction jointly fit multiple biomarkers as outcomes. This implies
that, even for patients who lack data in one of the measures due to short
follow-up time, we can expect better prediction compared to using a marker-
specific model as we are borrowing strength from the information seen in other
measures. We investigate the effect of jointly fitting multiple longitudinal
outcomes and further evaluate our model by comparing to empirical models
that directly models the critical events as the outcome. Another important
feature of the prediction model is that it generates real-time prediction of risk
as new data are observed without re-fitting the model.
The aforementioned methods are developed considering their use in the
clinic to communicate a person’s likely disease status, past trajectory, and
predictions of what is expected in the coming period for scleroderma patients.
In the current practice of medicine, a clinician has access to historical and
current data only about the patient at hand. That information is not typically
organized or presented in a fashion for the clinician to readily appreciate the
current status relative to its past. In addition, the patient’s data are not placed
within the context of other similar patients. For example, outcomes for prior
similar patients are not typically available. Clinicians therefore are forced to
make qualitative judgements about the patient’s status, trajectory, and likely
benefits of different treatments, not fully informed by either the patient’s own
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data or the experiences for other similar patients.
In order to improve patient care, we construct a web-based application
that shows a patient’s longitudinal data in multiple organ systems visualized
against those of other similar patients in selected clinical subgroups. Chapter
4 presents the design of the visualization tool, which provides the aggregate
clinical phenotype and longitudinal data in a snapshot view. The tool includes
cumulative disease manifestations, autoantibody status, and medication his-
tory among many other clinically relevant parameters. Our ultimate goal is
to embed the tool within the clinical workflow used by physicians to guide
their interactions with patients, thereby improving shared medical decision
making. To do so, we must implement and test the utility of the interactive in-
terface to communicate visualizations of a patient’s and reference population’s
longitudinal data.
We further propose to study the value of this tool in the clinic by conduct-
ing a randomized clinical trial. The trial is designed to assess the usability and
shared decision making of the tool from the designer, provider and patient
perspective. Details of the evaluation of the tool are presented in Chapter
4. Once our visualization tools are implemented at Johns Hopkins and ap-
proved for wider use based upon the clinical trial designed here, we will
enhance the tool by including predictions of future trajectories and the risks
of organ-specific complications as described in the previous chapter. We will
use a similar protocol to test the utility of the enhancements. We will then





data to estimate individuals’
trajectories with application to
scleroderma
2.1 Introduction
Scleroderma or systemic sclerosis is an autoimmune disease characterized by
dysregulation of the immune system, vasculopathy and fibrosis of multiple
organ systems, including the skin, heart, lungs, kidneys, gastrointestinal tract,
and blood vessels (Pattanaik, Brown, and Postlethwaite, 2011). In the United
States, scleroderma has annual incidence of 19.3 new cases per million adults
and prevalence of 276 cases per million adults (Mayes et al., 2003). Although
the disease is uncommon, scleroderma is a one of 80 related autoimmune
diseases that, in aggregate, comprise the 3rd most prevalent set of chronic
diseases after cancer and heart disease (Fairweather, Frisancho-Kiss, and
Rose, 2008). Scleroderma patients suffer from high morbidity and mortality
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with a median survival of 11 years (Mayes et al., 2003; Denton and Khanna,
2017). Mechanisms that cause the pathology still remain unknown but are
thought to be common to many other autoimmune diseases with higher
aggregate prevalence, and treatment is customized to the individual organ
systems involved in a given patient (Steen, 2008; Shah and Wigley, 2013).
Moreover, there is a wide heterogeneity among patient populations in terms
of clinical manifestations, response to treatment, rate of disease progression,
and survival, which adds another layer of complexity in understanding and
treating scleroderma (Allanore et al., 2015).
Given the substantial heterogeneity within the disease, clinicians and scien-
tists have been working to identify more homogenous patient subgroups that
are likely to share underlying disease mechanisms and treatment strategies.
Since the first description of scleroderma in 1842, understanding of the disease
has advanced through finding and analyzing subgroups defined by the extent
of skin involvement, lung involvement, or autoantibody profiles (Steen, 2008).
Identifying such subgroups is essential to understanding the etiology of the
disease and consequently to clinical treatments since it is known that patients
of the same clinical or demographic subtype tend to share similar prognosis
(Shah and Wigley, 2013; Denton and Khanna, 2017). Hence, it is crucial to
identify patients with rapid progression or at high risk of organ failure and
the associated biomarkers such as patterns in autoantibody profile.
To accurately measure patients’ health state and rate of progression at a
given moment, we present a method of optimally defining population and
individuals’ health trajectories. For many chronic diseases, patients’ health
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state is reflected in longitudinal clinical measures and/or occurrences of
clinical events over their course of disease. The scleroderma dataset has
characteristics that are common in many problems where the individual unit’s
trajectory is the focus. We observe multivariate longitudinal measures at
irregular observed times for each patient which composes the cohort. Of the
continuous outcomes of interest, some follow non-Gaussian distributions. We
also have multiple predictors clinically known to influence the outcomes that
need to be considered. In this chapter, we focus on building models that
flexibly describe the population and individual’s trajectories keeping such
characteristics of the data in mind.
Modeling trajectories in multiple dimensions involves a choice of whether
to jointly model all markers in a single model or to model each marker in
separate models. Traditionally, marker-specific models are widely used to
estimate health trajectories, but the questions of whether it is advantageous
to use a joint model have also been raised and answered in multiple settings
over many years. In order to fully utilize information in multiple longitudinal
markers, theoretically, we need to fit a joint model of all markers as opposed
to marker-specific models. We present a Bayesian hierarchical model of mul-
tiple longitudinal markers to estimate population, clinical subgroups, and
individuals’ trajectories taking the nested structure of the data into account.
The fitted model describes population disease progression in continuous time
as well as correlations among markers from different organ systems.
We focus on quantifying the performance of the joint model to marker-
specific models by deriving general formulae measuring the relative efficiency.
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The approach is somewhat unique in that we focus on the performance of
the two models on individual patient trajectories rather than the average
trajectories for subpopulations. We specifically investigate inefficiencies of
fitting marker-specific models for each patient and describe how they are
associated with the characteristics of the patient’s data. We examine in detail
the implications of the formulae on the scleroderma data, but the statistical
methods presented can easily be generalized for application to diverse chronic
diseases where biomarkers’ trajectories are of clinical importance.
2.2 Methods
2.2.1 The Johns Hopkins Scleroderma Cohort
The Johns Hopkins Scleroderma Center Cohort, one of the largest internation-
ally, provides a unique opportunity for the development of a trajectories-based
prediction tool for Scleroderma patients. In this retrospective/prospective
dynamic entry cohort, the clinical states of over 4000 patients have been col-
lected at baseline and every 6 months throughout the duration of the study
that started in 1990 and continues today. The data comprises the following
information:
1. demographic factors (date of birth, gender, race, ethnicity)
2. disease confirmation (classification criteria including ACR and CREST
criteria) and timing of disease onset (both Raynaud’s phenomenon and
first non-Raynaud’s symptom)
3. disease subtype (limited or diffuse based on extent of skin involvement)
9
4. disease severity scores (modified Medsger Severity Scale, based on 7
organ system scales)
5. exposure variables (family history, tobacco history, other exposures) and
medication history
6. quality of life measures (SSc Health Assessment Questionnaire, 3 dysp-
nea scales, among other patient reported outcome measures)
7. history of cancer; cancer diagnosis date, site, histology, treatment (surgery,
chemotherapy, radiation therapy, immunotherapy) if applicable
8. clinical and research laboratory data including autoantibody status
9. all pulmonary function tests, echocardiograms, and right heart catheteri-
zation (RHC) results.
In this paper, we model the latent health state for pulmonary function
measured by the standardized percent predicted forced vital capacity (pFVC)
and standardized percent predicted diffusing capacity for carbon monoxide
(pDLCO), cardiac function measured by right ventricular systolic pressure
(RVSP) and left ventricular ejection fraction (EF), and cutaneous involvement
measured by the modified Rodnan skin score (mRSS) since individuals’ dis-
ease onset. As is the clinical tradition, disease onset is defined by the earlier of
the onset of Raynaud’s phenomenon and first non-Raynaud’s symptom.
Prior to analysis, all five measures are preprocessed using quantile normal-
ization. Let Yk be a vector of the observed values from each measure k = 1, ..., 5.
The quantile-normalized vector for each k is obtained by Φ̂−1 ◦ Ĝk(Yk), where
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Ĝk is an estimated distribution of the vector Yk and Φ̂
−1 is the inverse of the
standard normal distribution. To calculate the quantile normalized values, ob-
servations from each measure are sorted in ascending order, paired with and
given the values of the corresponding percentiles calculated from a standard
normal distribution.
Lastly, RVSP and mRSS are transformed by multiplying them by -1 so that
increase/decrease in all five measures indicates better/worse health status.
The common scale is especially useful when aggregating predicted latent
health trajectories to generate a single trajectory characterizing overall health
state of patients’ over time.
2.2.2 Statistical models of trajectory
The linear mixed model (LMM) is widely used to describe changes in a single
approximately-Gaussian longitudinal outcome over time. LMMs are com-
monly used in observational studies, as they describe the correlation among
repeated measures of the same subjects and estimate subject-specific effects
while naturally handling irregularly spaced or/and unbalanced data (e.g.,
Brown and Prescott, 1999; Diggle et al., 2002). In his seminal papers (Harville,
1976 and Harville, 1977), Harville established the framework of the LMM and
showed that random effects estimators are the best unbiased linear predictors
(BLUP) with known covariance parameters. The result is derived by extend-
ing the Gauss-Markov theorem, which was previously used to prove that
the general linear mixed model (GLMM) provides the best linear unbiased
estimator (BLUE) (Graybill, 1976). For a single outcome, Potthoff and Roy,
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1964, Rao, 1965, and Grizzle and Allen, 1969 developed methods of estimation
and inference for the regression parameters in the case of complete, balanced
data. Laird and Ware, 1982 extended the LMM framework to accommodate
unbalanced data captured at possibly irregular times.
The multivariate linear mixed (MLMM) is an extension of the LMM for
the analysis of multiple outcomes. The MLMM was first fit using complete
and balanced data in Reinsel, 1984, then Shah, Laird, and Schoenfeld, 1997
presented parameter estimation via the EM algorithm for bivariate outcomes
with possibly missing responses. The variations and applications of MLMM
includes Sammel, Lin, and Ryan, 1999, Fieuws and Verbeke, 2004, and Wang
and Fan, 2012 among others.
In the presence of multivariate longitudinal observations measured for
individuals, both LMM and MLMM are in common practice. The LMM
approach estimates the population and individual trajectories of each out-
come independently of the others, while the MLMM additionally captures the
between-measure correlations induced by correlated random effects and ran-
dom error terms. An important question is how much worse are the regression
coefficients estimated from biomarker-specific LMMs performance where the
correlations among the error terms are ignored relative to the corresponding
coefficients estimated from a single MLMM. In early work on this question
Bloomfield and Watson, 1975 derived expressions for that combinations of the
design matrix and residual variance matrix for which the inefficiency of the
least squares estimates compared to the BLUE is the worst possible. A similar
idea was explored by Tukey, 1948. He quantified the maximum inefficiency
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caused by using a misweighted mean as compared to the optimally weighted
mean.
Cases in which the gain in efficiency is the largest possible have also been
studied under the "seemingly unrelated regression" (SUR) framework. A SUR
comprises a set of linear regression equations where each equation describes
the relationship between a different outcome and its associated predictor
variables. Zellner showed that the coefficient estimation using the Aitken’s
generalized least squares (GLS) (Aitken, 1934) is asymptotically more efficient
compared to the OLS, and that the efficiency increases as the error terms
from different equations become more cross-correlated and as the predictor
variables in different equations become less correlated. Zellner and Huang,
1962 further established the properties of the efficient estimator and proved
that the GLS also yields a minimal generalized MSE of the predicted values.
Oliveira and Teixeira-Pinto, 2015 applied Zellner’s result to the case in which
the outcomes share some predictors in common. He showed that GLS is more
efficient only for the outcome-specific predictors.
In this paper, we study the efficiency of the MLMM relative to a set of
outcome-specific LMMs using the scleroderma case study as the context. We
consider three parameters of interest: the fixed effects regression coefficients,
the random effects for each individual, and predicted values for each interval
over time. We work under the assumtion that missing data are missing at
random (MAR) (Rubin, 1976). For estimation of the fixed effects parameters,
we first approach the problem in the context of the SUR framework (see Section
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2.2.5). We introduce a method to quantify the inefficiency of the outcome-
specific LMM relative to the MLMM in the population level parameters and
individual level predictions.
2.2.3 Notation
Let Yijk be the observed value for the kth measure for person i = 1, . . . , m at
the jth visit j = 1, . . . , nik, at time since onset tijk and, let Yik be the vector of
Yijk for j = 1, . . . , nik. Xik and Zik are (nik × pk) and (nik × qk) known matrices
of full rank, and βk and bik are pk × 1 and qk × 1 measure-specific vector of
parameters for fixed and random effects. Let ni = ∑Kk=1 nik and eik random
measure-specific within-subject error term.








The linear mixed effects model is written as
Yi = Xiβ + Zibi + ei, i = 1, ..., m
where
β = (βT1 , ..., β
T
K)











bi = (bTi1, ..., b
T
iK)
T ind∼ NKq(0, D)
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ei = (eTi1, ..., e
T
iK)
T ind∼ Nni(0, Σi).
Letting
Y = (YT1 , ..., Y
T
m)







b = (bT1 , ...b
T
m)
T, e = (eT1 , ...e
T
m)






we can write the above model more compactly in the standard linear mixed
model form
Y = Xβ + Zb + e
where
Y ∼ N(Xβ, V), V = ZΓZT + Σ
b ∼ N(0, Γ), e ∼ N(0, Σ).
2.2.4 Defining combined and separated models
In the above specification, D and Σi are (Kq×Kq) and (ni × ni) positive definite
matrices, respectively. The K (q × q) and (nik × nik) measure-specific block
matrices for D and Σi on the diagonals represent within-measure covariance
of random effects and random errors, respectively. The off block diagonals
of D and Σi represent the covariances of random effects and random errors
across measures. If they are set equal to zero matrices, then the mixed effects
model of K measures reduces to what is equivalent to K measure-specific
univariate mixed effects models. We call this model the "separated" model;
the model with the unrestricted D and Σi is called the "combined" model.
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For the separated model,
Yi = XiβS + ZibSi + ei, i = 1, ..., m
where
bSi ∼ NKq(0, DS), ei ∼ Nni(0, ΣSi)







For the combined model,
Yi = XiβC + ZibCi + ei, i = 1, ..., m
where
bCi ∼ NKq(0, DC), ei ∼ Nni(0, ΣCi)







For simpler notation, let WS = V−1S , WC = V
−1




V−1Ci in following sections.
2.2.5 Separated models and seemingly unrelated regressions
The fixed effects estimates β̂C from the combined model are generalized least
squares (GLS) estimates, first described in Aitken, 1934. The Aitken model
takes the form of Y = Xβ + ϵ with the first two moments of ϵ defined as
E(ϵ|X) = 0 and Cov(ϵ|X) = V, where V is a known positive definite matrix.
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Under these assumptions, the GLS estimator of β is β̂ = (XTV−1X)−1XTV−1Y.
It is the best linear unbiased estimator (BLUE); in other words, β̂ is the "best"
estimator in the sense that it has the minimum variance among the class of
linear unbiased estimators of β. Since our model defined in 2.2.3, assumes a
positive definite matrix V = ZΓZT + Σ, we know that β̂C is the most efficient
estimators of the fixed effects assuming known variance. The result implies
that even though β̂S and β̂C are both unbiased estimators of β as shown in
Appendix B.1, there is loss of efficiency in using β̂S as β̂C is the most efficient.
There are, however, situations where the separated models yield estimators
as efficient as those estimated in a single multivariate outcome, as introduced
in Zellner, 1962. We show Zellner’s results under his SUR framework and
investigate whether or not the results are applicable to the estimates of fixed
effects and random effects in our model.
We start with a simplified version of our model. Suppose each of our K
measurements includes m individuals responses collected at times t = 1, ...T
and n = m × T. The seemingly unrelated regression equations are defined as:
Yk = Xkβk + ϵk, i = 1, ..., K
where Yk and ϵk are (n× 1), Xk is (n× p) and βk is (p× 1). The covariances
in the errors or disturbance terms ϵk are defined across the five measures by
Cov(ϵkt, ϵlt) = σkl In.
It is possible and often convenient to estimate the regression coefficients
for each outcome separately. This is the reason that the equations are called
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seemingly unrelated regression equations. However, the equations are con-
nected to one another by the correlation among the error terms across the
equations.










X1 0 0 · · · 0
0 X2 0 · · · 0
0 0 X3 · · · 0
0 0 0 . . .
...















⎞⎟⎟⎟⎟⎟⎠ = Xβ + ϵ.
With the following covariance matrix for the error term ϵ,
V(ϵ) =
⎛⎜⎜⎜⎝
σ11 In σ12 In · · · σ1K In




σK1 In σK2 In · · · σKK In
⎞⎟⎟⎟⎠ =
⎛⎜⎜⎜⎝
σ11 σ12 · · · σ1K









σkl is the covariance between the error term in the equation for measure k
and that in the equation for measure l, and σkk is the variance of the error term
in the equation for measure k. The above formulation assumes that σkk and σkl
are constant for all observations within respective measures, that there is no
correlation between errors of observations collected at different times implying
no serial correlation of error terms. More importantly, we are disregarding
all within-individual correlation captured by introducing random effects. We
will later accommodate our mixed effects model assumptions and modify
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the results accordingly, but we first demonstrate Zellner’s results using our
simpler model.




σ11 In σ12 In · · · σ1K In




σK1 In σK2 In · · · σKK In
⎞⎟⎟⎟⎠ =
⎛⎜⎜⎜⎝
σ11 σ12 · · · σ1K









The first of the two conditions under which the equation-by-equation
model yields estimators as efficient as β̂ is when the error terms have a
diagonal covariance matrix such that σkl = σlk = 0. When we force all
covariance terms across measures to be 0, the GLS estimator reduces to
five single-equation least-squares estimators. The less obvious condition
is X1 = X2 = · · · = XK.







































Hence, β̂ reduces to a vector of single-equation estimators even with cor-
related error terms. In practice, this implies that when all measures have the
same design matrix (i.e. data for all K measures measured at the same time
and function of time is the only explanatory variable for each measure), we
obtain the same population estimates from the equation-by-equation model
and the joint model. We now investigate if these two results also hold under
the assumptions of the combined model.
The main difference between the SUR model and the combined model is
that patient-specific random effects are introduced. The fixed effect estimates
of the combined model is β̂C = (X
TWCX)−1XTWCY where W−1C = VC =










G11 G12 · · · G1K





































σ11 σ12 · · · σ1K




σK1 σK2 · · · σKK
⎞⎟⎟⎟⎠⨂︂ In
Let Zki be the random effects design matrix of kth measure of ith person,
Zk =
⨁︁m







ImZT1 + σ11 In Z1G12
⨂︁
ImZT2 + σ12 In · · · Z1G1K
⨂︁
ImZTK + σ1K In
Z2G21
⨂︁
ImZT1 + σ21 In Z2G22
⨂︁
ImZT2 + σ22 In · · · Z2G2K
⨂︁






ImZT1 + σK1 In ZKGK2
⨂︁
ImZT2 + σK2 In · · · ZKGKK
⨂︁
ImZTK + σKK In
⎞⎟⎟⎟⎠
The off-diagonal block matrices of VC explaining the covariance of the
observations across measures in time become 0 when we have a diagonal
covariance matrix for error terms (σkl = σlk = 0) and additionally for random
effects (Gkl = Glk = 0). Then, VC = VS and β̂C = β̂S, and βŜ becomes BLUE.
The remaining question is whether β̂C = β̂S in the case of X1 = · · · =
XK. As shown above, Zellner’s result largely depends on the covariance
of the error terms adopted in the SUR model, where it can be written as
Σ
⨂︁
In. But the form of VC makes it clear that it cannot be decomposed into
a Kronecker product of a matrix with scalar variance terms and the identity
matrix. Therefore, β̂C does not take the same form as β̂S and β̂S is not an
efficient estimator. To conclude, estimation of the fixed effects is guaranteed
to be more efficient when jointly modeling the measures as compared to
separate modeling, except in the obvious case where all the covariance terms
across measures are 0 in which case the two models are equivalent. Having
established that separated models produce inefficient estimates of fixed effects,
the question remains how inefficient are they? Is the inefficiency enough to
warrant the burden of jointly modeling the outcomes in situations where the
separated models meet the clinical objectives?
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2.2.6 Comparing estimates of combined and separated mod-
els
Our interest lies in understanding the advantages and disadvantages of using
the combined model instead of the separated model when both address the
main scientific or clinical question. This is typically the case when the ques-
tions are about within-measure contrasts, rather than those that involve multi-
ple measures. Because the combined model quantifies the covariation across
measures, there are inferences about cross-measure contrasts that require use
of the combined model. Examples are whether our two lung measures are
sufficiently strongly associated that only one is required for clinical decision
making, or to what extent disease progression in the skin forewarns future
progression in the lung. In this section, we consider the relative merits with
respect to accuracy and precision of the combined and separated models in
estimating:
1. fixed effects coefficients that represent population average trajectories β̂
2. individuals’ random effects b̂i that represent their deviation from the
average trajectories
3. individual patients’ estimated trajectories ŷi that are a linear combination
of β̂ and b̂i.
Our strategy is to compare the theoretical mean squared error (MSE) and
its variance and bias components for each of β̂, b̂i, and ŷi obtained from the
combined and separated model. Since β̂, b̂i, and ŷi are functions of the variance
estimates, we first obtain the variance estimates by fitting the combined model.
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We fit a linear mixed effects model with measure-specific smooth function
of time as fixed effects plus random intercept and slope. From the model,
we obtain fully parametrized covariance estimates of DC and WCi, which are
assumed to be the true covariances of the underlying population. By taking
block diagonal elements of DC and WCi, we subsequently obtain DS and WSi.






The mean squared error (MSE) of an estimator θ ∈ Rd is defined as




(θ̂ j − θj)2) = Tr(Var(θ̂)) + ||Bias(θ̂)||2.
Then, as both estimates are unbiased,
MSE(β̂S, β) = Tr(var(β̂S)) = Tr((X
TWSX)−1XTWSVCWSX(XTWSX)−1)
MSE(β̂C, β) = Tr(var(β̂C)) = Tr((X
TWCX)−1).
We use the conditional expectation of the random effects given the ob-
served data for patient i as our estimates of their random effects. These
conditional expectations under the combined and separated models are given
by:
b̂Si = DSZTi WSi(yi − Xi β̂S)
b̂Ci = DCZTi WCi(yi − Xi β̂C).
If we condition on the true random effect bi, then b̂Si and b̂Ci are both biased
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toward 0. Their MSEs are defined as the conditional expected squared differ-
ence between the predicted values above and the true value of the random
effect. We calcuate the average value of the MSEs over the distribution of bi.
For the separated model,




i (WSi − WSiXi(XTWSX)−1XTi WSi)ΣCi






2} = Tr{(DSZTi (WSi − WSiXi(XTWSX)−1XTi WSi)Zi − I)DC
×(DSZTi (WSi − WSiXi(XTWSX)−1XTi WSi)Zi − I)T}.
For the combined model,




i (WCi − WCiXi(XTWCX)−1XTi WCi)ΣCi
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2} = Ebi{Tr((E(b̂Ci|bi)− bi)(E(b̂Ci|bi)− bi)
T)}
= Tr{(DCZTi (WCi − WCiXi(XTWCX)−1XTi WCi)Zi − I)DC
×(DCZTi (WCi − WCiXi(XTWCX)−1XTi WCi)Zi − I)T}.
Lastly, predicted values for patient i under the two models are
ŷSi = Xi β̂S + Zib̂i = Xi β̂S + ZiDSZ
T
i WSi(yi − Xi β̂S)
ŷCi = Xi β̂C + Zib̂i = Xi β̂C + ZiDCZ
T
i WCi(yi − Xi β̂C).
MSE of the predicted values to their true trajectory for the separated model
is




















2} = Tr(({MSiXTi + ZiDSZTi }WSi − I)ZiDCiZi
×({MSiXTi + ZiDSZTi }WSi − I)T)
where MSi = (Xi − ZiDSZTi WSiXi)(XTWSX)−1.
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For the combined model,




















2} = Tr(({MCiXTi + ZiDCZTi }WCi − I)ZiDCiZi
×({MCiXTi + ZiDCZTi }WCi − I)T)
where MCi = (Xi − ZiDCZTi WCiXi)(XTWCX)−1.
For derivations, see Appendix A.1.
To quantify the maximum benefit of using the combined model, we first
calculated the combined/separated ratio of measure-specific mean squared
errors, biases, and variances when the variance parameters are assumed to
be known. We used the estimated posterior modes for the unknown variance
parameters as if they were the true values. We then accounted for the fact that
the variance parameters are unknown and must be estimated. It is expected
that some or all of the advantage of the combined model might be lost. We
approximated the posterior distribution of the MSEs, biases, and variances.
For each of the 500 random samples from the joint posterior, we calculate
the errors, biases, and variances of the two models using the formulae above.
We then compare the ratio posterior distributions to the previously obtained
ratios that ignored the uncertainty in the variance parameters.
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2.2.7 Efficiency gained by the degree of correlation across patient-
specific trends
Our conjecture is that the measures that are heavily correlated are the ones
that benefit the most from fitting the combined model and measures that have
weaker correlation will only have marginal gains. We further test this idea by
gradually amplifying the correlation of one measure’s random effect to those
of other measures and investigate the effect of higher correlation on efficiency
gain for that measure.
We vary the degree of correlation among random effects for the EF and rest
of the measures as follows. From the combined model, we obtain a correlation






In Cb, we increase the absolute value of the correlation between the EF random
slope and those of all other measures to 0.1, 0.2, and 0.3 while retaining the
sign of the original correlation. To ensure the resulting covariance matrices
are positive-semi-definite, we use a slightly modified version of the spectral
decomposition method introduced in Rebonato and Jäckel, 2001. Let’s call
the modified correlation matrices C0.1, C0.2, and C0.3. We decompose each
matrix into its eigenvalues and eigenvectors. For each set of eigenvalues, we





0.3. Then, the resulting covariance matrices D̂0.1, D̂0.2,













0.3 respectively. The correlations between EF




0.3 might not have
the magnitude of exactly 0.1, 0.2, and 0.3, respectively and the calculated
correlations are shown in the results section and appendix.
2.2.8 Fitting the separated and combined models
In order to investigate the advantages and disadvantages of the two models
as they might be used in statistical practice, we sought to fit the models us-
ing existing open-source software. An appropriate software package should
accommodate the following conditions: (1) the number of repeated measure-
ments and the times of measurement can differ across the subjects and the
measures without requiring explicit imputation of outcomes and (2) the co-
variance across random effects and measurements can be flexibly constructed
to represent the correlations observed in the scleroderma case-study data.
To reflect changes in patients’ health over time since disease onset, the
fixed effects of our model included natural splines of time with 3 degrees
of freedom, age of onset, race, sex, skin type, presence of three common
autoantibodies, and the interactions of each of the baseline covariates listed
above with the natural spline of time. Patient specific intercept and linear
time are included as random effects. Standard linear mixed model software
including R packages lme4 (Bates et al., 2015) and nlme (Pinheiro et al., 2019)
can easily fit the separated models. However, in this case-study, the algorithm
fails to converge despite substantial efforts to tailor the convergence tuning
constants. The combined model with saturated random effects and residual
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covariances requires estimation of 40 + 10 additional parameters in the random
effects and residual covariance matrices, respectively, compared to those of
the separated model.
A second alternative was to use a Bayesian Markov Chain Monte Carlo
(MCMC) algorithm, where we can obtain posterior distributions of all param-
eters of interest. We successfully fit the combined model using an R package
MCMCglmm (Hadfield, 2010). For the fixed effects of both models, we use a
diffuse independent normal prior centered around zero with a large variance
(108). Weakly informative inverse-Wishart priors are placed on random effects
and residual covariance matrices. After examining the distribution of our
data, we set the prior distribution of the random intercepts to have the mode
of 1 and those of random slopes to have the mode of 0.005, with 10 degrees
of freedom. The prior distribution of the residual covariance matrix takes
the mode of 1 for each measure, with 5 degrees of freedom. The degrees of
freedom are chosen to make the distributions as diffuse as possible while
guaranteeing them to be valid inverse-Wishart distributions. Scale matrices




For the following analyses, we include 581 "data-rich" patients who have
at least 4 data points from disease onset to 40 years later for each of the 5
measurements. Table 2.1 presents the mean and standard deviation of the
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number of observations per patient.
pFVC pDLCO EF RVSP mRSS
Mean 12.83 12.40 9.13 7.47 19.09
StdDev 6.20 6.01 3.71 3.28 7.61
n 6136 5789 4281 3281 9055
Table 2.1: Summary statistics of patients’ number of observations
Table 2.2 summarizes the distribution of the continuous and binary vari-




median (IQR) 41.65 (31.61, 51.17)
mean (sd) 41.42 ± 14.02
maximum 83.45
Race

















Table 2.2: Characteristics of the cohort
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2.3.2 Estimating latent trajectory
2.3.2.1 Population average trajectory
From the simulated parameter values from the posterior distribution, we
calculate population mean trajectories for each of the five measures. Figure
2.1 (bottom) presents the posterior mean biomarker value as a function of
time with 95% credible intervals defined to be the interval from the 2.5 to 97.5
percentiles of the posterior draws. We observe a small decline in pFVC, a
large decline pDLCO, a small decline in the heart measure RVSP, but a strong
improving trend for the skin condition mRSS.
Figure 2.1: Observed and predicted population average trajectories
The set of five plots in the top row of Figure 2.1 shows the preprocessed
observed data. Each individual’s longitudinal measurements are shown as
grey lines in the background. The blue smoothing lines connect the empirical
mean value at each time point with nominal 95% confidence intervals that
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incorrectly ignore the correlations among the repeated measurements for an
individual. We observe upward trend in the observed population trajectory
for pFVC and pDLCO while the predicted trajectories of the two measures
show decreasing trend. This can be explained by selection bias; patients with
more negative trajectories drop out more often. The observed trends only
reflect the average of observed values of the remaining healthier patients.
Figure 2.2: Predicted average trajectories for autoantibody groups
The health trajectories serve as a useful tool to estimate disease prognosis
for scientifically-defined subgroups. We estimate average health trajectories
for three autoantibody groups by fitting the combined model. In Figure
2.2, the predicted mean trajectories and their 95% credible intervals for the
five measures are shown for each patient subgroup: those positive for anti-
centromere antibodies (ACA), anti-RNA polymerase (RNAPol), and anti-Scl-
70 antibodies (Scl-70). The autoantibody subgroups demonstrate distinct paths
most notably in the two lung measures pFVC and pDLCO and in the first 10
years since onset for mRSS. Patients tested positive for ACA tend to have better
prognosis for lung and skin. RNAPol and Scl-70 groups have lower initial
levels and steeper negative slopes for the lung measures and positive slopes
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for mRSS - indicating more advanced skin and lung disease at disease onset
with progressive lung disease over time and improving cutaneous disease.
2.3.3 Separated and combined models
2.3.3.1 Measure-wise correlation
Figure 2.3: Empirical correlation matrix
We display the correlation across the observed measures at different times in
the data and compare the correlation structures assumed and estimated by
the two models. Pairwise correlations of observations from all patients for 11
years (years 0,...,10 since the disease onset) are calculated and plotted (Figure
2.3 (left)) using range of colors from red, white, and blue each representing
correlation of 1, 0, and -1, respectively. The 11 by 11 block matrices on the
diagonals shows the degree of correlation in patients’ repeated observations
over time for each of the five measures. Looking along the block-diagonal,
one observes that the two lung measurements and mRSS are highly correlated
with their respective past observations, while observations of the two heart
measures have less serial correlation. The 11 by 11 off-diagonal block matrices
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show the degree of correlation for different pairs of measures with leads
and lags. We observe high positive correlation for the two lung measures
which suggests that there could be gains in efficiency when modeling the two
measures jointly. We observe some degree of positive correlation between
RVSP, mRSS, and the two lung measures; the EF observations appear to be
uncorrelated with any other measure including the other cardiac measure.
The estimated random effects correlation matrix C
′
b calculated from D̂C
captures the associations among random levels and linear trends for each
pair of measures. In order to investigate the degree of correlation of patient-
specific trends, we present Table 2.3, which only includes the random slope
components of C∗b . We observe a correlation of 0.64 between the latent trends
of pFVC and pDLCO. The correlations of RVSP random slope with that of
pFVC and pDLCO are estimated to be 0.37 and 0.40, respectively. mRSS
random slope also have positive correlation, 0.27 and 0.20, with pFVC and
pDLCO random slope. The EF trend has little or no correlation with pFVC
and RVSP trends and small correlations with pDLCO and mRSS.
In Figure 2.3 (middle and right), the empirical correlation matrices of the
combined and separated models are plotted using the covariance estimates
from the two models, D̂C and D̂S. Recall that the combined model allows
correlation among the five measures, while the separated model does not.
As shown in Figure 2.3, the combined model captures patterns in the within-
measure and across-measure empirical correlation matrices of the data quite
well, while the separated model only captures within-measure correlations.
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pFVC pDLCO EF RVSP mRSS
pFVC 1.00 0.64 0.00 0.37 0.27
pDLCO 0.64 1.00 -0.12 0.40 0.20
EF 0.00 -0.12 1.00 -0.03 0.10
RVSP 0.37 0.40 -0.03 1.00 0.13
mRSS 0.27 0.20 0.10 0.13 1.00
Table 2.3: Correlation of random slopes across measures from Cb
2.3.3.2 Comparing bias and efficiency
Using the formulas derived in 2.2.6 we compare MSE, bias and variance
components of: (1) the fixed effects estimates β̂C and β̂S; (2) random effects
estimates b̂Ci and b̂Si; and (3) the predicted values ŷCi and ŷSi. All three
estimands of interest are functions of the design matrices (X and Z) and
covariance matrices (DC, DS, ΣSi, and ΣCi). We construct design matrices for
each individual using observed times at which the five measurements are
taken based on the model described in 2.2.8. From the model, we also estimate
the population covariance of the random effects DC and population residual
covariance ΣCi. In this section, we use the finite sample posterior estimates
of the theoretical variances obtained by taking the posterior mean of the
MCMC estimates of DC and ΣCi. DS and ΣSi are constructed by forcing the off-
diagonal terms of DC and ΣCi to be 0, indicating the absence of across-measure
variance terms of the separated model.
Population average trajectory estimation
Efficiency gain in estimating population health trajectory can be evaluated
by comparing the variance components of fixed effects estimates of the two
models. In Table 2.4, we present MSE(β̂C, β)/MSE(β̂S, β), the ratio of MSE of
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overall and measure-wise fixed effects of the combined model to the separated
model.
Overall pFVC pDLCO EF RVSP mRSS
MSE Ratioβ 0.97 0.98 0.97 0.99 0.95 0.99
Table 2.4: Ratio of MSE of overall and measure-wise fixed effects of the combined
model to the separated model
Assuming known variances, the overall MSE in estimating fixed effects
is reduced by only 3% when using the combined model compared to fitting
the separated model. Since both fixed effect estimates for the separated and
combined models (β̂S and β̂C) are unbiased (see Appendix B.1), the reduction
in MSE solely comes from a variance reduction. The comparative advantage
is more apparent for RVSP but not for EF. Clinically, the result implies that we
need 3% more data when fitting the separated model compared in estimating
population mean trajectories as efficiently as the combined model, and 5%
more data for RVSP alone. This small gain in efficiency does not account for
the uncertainty in the variance parameters so is not likely to be worth the
increased modeling demands of fitting a combined model.
Estimating random effects
Patients’ deviations in the level and trend from the average population
trajectory is captured by the random intercept and slope estimates. As shown
in Section 2.2.6, the random effects estimates are a linear combination of the
patient-specific level and trajectory estimates and the population estimates.
Hence, depending on the amount and characteristics of individual’s data, we
can expect variation among patients in the MSE, squared bias, and variance.
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In this section, we first present the overall effect of fitting the combined model
on the random effects and random slope estimates by calculating the average
of patients’ three estimates for each of the five measures.
The ratios of the three estimands are calculated as the following:
MSE Ratiobi = Ebi{MSE(b̂Ci, bi)}/Ebi{MSE(b̂Si, bi)}
Squared Bias Ratiobi = Ebi{||Bias(b̂Ci)||
2}/Ebi{||Bias(b̂Si)||
2}
Variance Ratiobi = Ebi{Tr(varb̂Ci|bi(b̂Ci|bi))}/Ebi{Tr(varb̂Si|bi(b̂Ci|bi))}
pFVC pDLCO EF RVSP mRSS
Mean MSE Ratiobi 0.98 0.96 0.98 0.95 0.99
Mean Squared Bias Ratiobi 1.00 0.97 0.98 0.94 0.99
Mean Variance Ratiobi 0.99 1.01 1.01 1.06 1.00
Table 2.5: Mean and the ratio of MSE, variance, and squared bias components of
random effects of the combined model to the separated model
In Table 2.5, we observe modest reductions in the MSE for the combined
model. We also observe that the advantage is mostly generated from reduction
in squared bias rather than variance. The reduced squared bias suggests
that the random effects estimators from the combined model are closer to
the true random effects on average compared to those from the separated
model. Similar to the population average trajectory estimation, we observe
greater average decrease in MSE and Squared Bias for RVSP than for the other
measures.
We also compare the means of three estimands only for the random slopes
of the two models in Table 2.6, where we observe similar patterns. Estimating
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random slopes using the combined model is most advantageous for RVSP
with smaller average MSE and squared bias.
pFVC pDLCO EF RVSP mRSS
Mean MSE Ratiobi 0.97 0.95 0.98 0.91 0.98
Mean Squared Bias Ratiobi 1.00 0.97 0.97 0.91 0.99
Mean Variance Ratiobi 0.99 1.01 1.03 1.08 1.00
Table 2.6: Mean and the ratio of MSE, variance, and squared bias components of
random slopes (trends) of the combined model to the separated model
Individual patients’ prediction
Individual’s predicted trajectory is a combination of estimated population
mean trajectories and individual specific trajectory fitted only through the
individual’s data points. The amount of shrinkage to the group mean from an
individual’s observed trajectory depends on the amount of her data. At the
limit of no observations, the best predicted trajectory for an individual is the
population mean trajectory, itself.
The ratios of the three estimands are calculated as follows:
MSE Ratioyi = Ebi{MSE(ŷCi, E(ŷi|bi))}/Ebi{MSE(ŷSi, E(ŷi|bi))}
Squared Bias Ratioyi = Ebi{||Bias(ŷCi)||
2}/Ebi{||Bias(ŷSi)||
2}
Variance Ratioyi = Ebi{Tr(varŷCi|bi(ŷCi|bi))}/Ebi{Tr(varŷSi|bi(ŷSi|bi))}
As was the case for the fixed effects, the mean gains in MSE by fitting
the combined model are minimal as shown in Table 2.7. The mean Squared
Bias Ratio and mean Variance Ratio are also qualitatively not different than
was observed for the fixed effects. Of course, the degree of benefit obtained
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from the combined model will vary among individuals. The size of this
heterogeneity is considered next.
pFVC pDLCO EF RVSP mRSS
Mean MSE Ratioyi 0.99 0.97 0.99 0.97 0.99
Mean Squared Bias Ratioyi 1.02 1.01 0.99 1.02 1.00
Mean Variance Ratioyi 0.99 0.97 0.99 0.96 0.99
Table 2.7: Mean of ratio of MSE, variance, and squared bias components of predicted
values of the combined model to the separated model
2.3.3.3 Heterogeneity in bias and efficiency gains by patient
In this section, we focus on the values and distribution of the MSE, bias
and variance for estimators of patients’ means, random effects and predicted
values. The MSE and its components are calculated using (1) asymptotic
variance estimates and (2) the posterior distribution of the variance estimates.
All patient-specific expected errors are summarized in Figure 2.4. Boxplots
for errors using the asymptotic variance are plotted in grey, and those using
the posterior distribution in orange. Since the MSE, bias, and variance are
transformed onto the log scale, a positive value indicates that the separated
model has smaller errors and a negative value indicates that the combined
model does.
As using the asymptotic variances yields a single population level estimate
for each measure, the point estimates are plotted in grey points in the top
three plots. The five grey points marking the measure-specific log ratios of
MSE (left) and variance (right) are equivalent to the MSE Ratioβ in Table 2.4
transformed to the log scale. The box plots in orange show the distribution of
the 500 estimands by each measure calculated using the 500 posterior MCMC
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Figure 2.4: Log ratio of MSE, variance and squared bias components of the combined
model to the separated model
samples for the variance estimates. We observe that the grey point estimates
are generally close to the center of the orange box plots. As the squared bias
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components are 0 for both measures, the log ratios are plotted at 0.
We also compared the patient-level log ratios for the random slope esti-
mates and predicted values. Three plots in the middle and bottom row show
measure-specific log ratios of 581 patients. The grey box plots characterize
the distributions of the log ratios using asymptotic variances. When using the
posterior variance samples, each patient has a distribution of the 500 copies
of the three estimands. To summarize the information in these distributions,
we take the mean of the 500 ratios and plot the logged values shown across
patients in orange box plots.
The most notable result is that there is a sizable amount of heterogeneity
for the patients’ log ratios, especially for pDLCO and RVSP. Most patients
benefit from the reduction in RVSP MSE ratios by fitting the combined model.
The gains in pDLCO are more noticeable for the 25th percentile of the patients.
The stretched out left tails of the pDLCO MSE for both random slope estimates
and predicted values indicate that some patients are estimated to have over
20% (≈ e−0.2) efficiency gains. The factors that influences the varying degrees
of efficiency gains across patients are further investigated in the next section.
Overall, the reduction in MSE results from the reduction in squared bias
for the random slope estimates and from the reduction in variance for the
predicted values. Comparing the magnitude of log ratios, the combined model
reduces the MSE the most for the random slope estimates compared to the
population estimates and predicted values. We conclude that there hardly is a
qualitative difference in the results from using asymptotic variance estimates
and using the posterior distribution of the variance estimates.
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2.3.3.4 Gains in efficiency by patient data characteristics
In this section, we present a series of post hoc analyses that investigate the
association between efficiency gains and patient data characteristics. From
previous sections, we observed that the reduction in MSE at all levels - pop-
ulation and individual - is the greatest for RVSP. We can intuitively relate
this result to the number of observations in each measure. In Table 2.1, RVSP
has the lowest average number of observations per patient. On average, the
two lung measures and mRSS have twice as much data as in RVSP. Hence,
utilizing information in the richer measures by fitting the combined model is
likely to result in improved estimation of the RVSP parameters.
Richness of data, however, cannot solely explain the efficiency gains. Both
EF and RVSP have sparse data, yet EF hardly benefits from fitting the com-
bined model at any level. Unlike RVSP, the degree of correlation between EF
and other measures are close to 0 as shown in Table 2.3. Using the method de-
scribed in Section 2.2.7, we increase the magnitude of correlation between EF
random slope and those of all other measures to 0.1, 0.2, and 0.3 as described
in Table 2.8. The estimated correlation matrices across random slopes with
varying degrees of correlations are in Appendix A.2.
pFVC pDLCO RVSP mRSS
Corr Data 0.00 -0.12 -0.03 0.10
Corr0.1 0.10 -0.10 0.10 -0.10
Corr0.2 0.20 -0.20 0.20 -0.20
Corr0.3 0.28 -0.28 0.29 -0.28









Figure 2.5: Log ratio of MSE, Variance, and Squared Bias of patient level deviations
of trends of the combined to separated model by varying degrees of correlation in
random slope of EF and other measures.
The effects of varying correlations on the EF log ratios are presented in
Figure 2.5. As the correlations of EF random slope and those of other measures
increase from the unmodified correlation estimated from the data (Corr Data)
to 0.3, we observe considerable reductions in MSE and squared bias. The
result illustrates that fitting the combined model is especially advantageous
when the patient level trends for one measure are more strongly correlated
with the others.
Finally, we present the influence of information in one measure on estima-
tion of the other in the presence of across-measure correlation. We focus on
pDLCO and pFVC, whose random slopes are highly correlated at 0.64 (Table
2.3). In Figure 2.6, we illustrate pDLCO patient level log ratios by the number
of pDLCO and pFVC observations. Generally, the MSE ratios for the random
slope estimates and predicted values are lower for patients with relatively
fewer pDLCO observations. The result implies that patients with rich pDLCO
data can obtain reasonable trajectory estimates by only modeling pDLCO,
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while patients with sparse pDLCO data are likely to benefit from improved
estimation by fitting the combined model.
Figure 2.6: Patient level log ratios of MSE, variance and squared bias components of
the combined model to the separated model for pDLCO.
Among these patients with fewer pDLCO observations, we identify the
subset of patients who benefit the most from fitting the combined model by
stratifying them into three groups by the relative number of pFVC and pDLCO
observations. We notice lower log MSE ratios for patients whose number of
pFVC observations is greater than that of pDLCO (points plotted in yellow in
Figure 2.6), whereas there are only minimal gains for those whose number of
pFVC observations is equal to or lower than that of pDLCO (points plotted in
green and red). From these results, we conclude that the available information
in the measure itself and other correlated measures together determine how
much an individual can benefit from fitting the combined model.
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2.4 Discussion
In this paper, we present our approach to estimating latent health trajectory
from multivariate longitudinal data. We define and compare the combined
and separated models with the aim of providing guidelines for modeling
when individuals’ trajectory is reflected in multiple longitudinal outcomes.
By the Gauss-Markov theorem, the combined model is known to yield more
efficient fixed and random effects estimates. However, the combined model is
also more complex and potentially less robust to misspecification. Our main
question is to what degree the assumed benefits outweigh the simplicity of
relying on separated models. We first extended the SUR framework to the
MLMM and showed that the separated model can only be as efficient as the
combined model if there is no correlation between the random effects and
random disturbance terms across different measures. Then we provided an
approach to quantify the efficiency gain in estimating the population level
parameters as well as the individual level predictors. We give general formulae
for the relative efficiency of estimators for the fixed effects, random effects and
predicted values. In our case study, we observe minimal gains in efficiency for
the fixed effect estimates by fitting the combined model. Gains in estimating
the random effects was the largest when the given measure is highly correlated
with other measures, and when the relative number of the observations in
that measure is smaller than those in other correlated measures.
In such cases, we observe gains in efficiency, that is smaller MSE, that
mostly results from reduced bias. For individuals who have only a few data
points available for a given measure, the data for the measure alone cannot
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accurately reflect the underlying disease state of the individual, and fitting
the separated model results in more shrinkage towards the measure-specific
mean and hence larger bias. The bias is reduced when fitting the combined
model, where the random effects estimator borrows strength from data-rich
measures. We also show that the results hold under the assumption of known
variance parameter and when we take the uncertainty in the variance into
account. Although we present the inefficiency in estimation that comes from
the misspecification of variance in the attempt to answer specific medical
questions pertaining to scleroderma, the approach can be flexibly generalized
to other applications. We proposed a framework to compare the performances
of the combined and separated models for the population and individual
level estimates, which can be applied to any setting where the individuals’
and population trajectory in higher dimension space need to be estimated.
However, it should be noted that the results are drawn assuming normal
population with MAR assumption. The effect on disparities from normality
and non-ignorable missingness on the results remains to be studied.
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Chapter 3
Predicting clinical events using
Bayesian multivariate linear mixed
models
3.1 Introduction
It is a major challenge to assess risks of critical events in chronic, multi-organ
diseases such as multiple sclerosis (Institute of Medicine, 2001), lupus (Zeller
and Appenzeller, 2008), and Parkinson’s disease (Jain, 2011). Scleroderma, an
autoimmune disease that is manifested by fibrosis of multiple organ systems,
may affect the skin, heart, lungs, kidneys, gastrointestinal tract, and blood
vessels. Severe organ involvement can result in early death (Pattanaik, Brown,
and Postlethwaite, 2011; Steen and Medsger, 2000). The 9-year cumulative
survival rate for diffuse scleroderma patients with severe organ involvement
was estimated to be 38% (Steen and Medsger, 2000). Mortality is highest due
to pulmonary and cardiac complications of the disease; 35% of scleroderma-
related death has been attributed to pulmonary fibrosis, 26% to pulmonary
arterial hypertension (PAH) and 26% to cardiac causes (Tyndall Anthony J. et
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al., 2010). Such events are commonly observed in scleroderma patients; for
example, pulmonary involvement has been reported in up to 25% of patients
at the early stage of diagnosis (Mcnearney et al., 2007). Hence, a major goal
is the early detection of patients who are most likely to progress at an early
stage of the disease, as this may provide a window of opportunity to intervene
before there is irreversible organ damage (Shah and Wigley, 2013).
In monitoring scleroderma, clinicians obtain longitudinal markers from
pulmonary function tests and echocardiograms to assess whether there is evi-
dence of disease activity or progression in the lung and heart. Left ventricular
ejection fraction (EF), right ventricular systolic pressure (RVSP), and percent
predicted forced vital capacity (pFVC) are examples of parameters that are
monitored to detect whether there is emerging cardiomyopathy, pulmonary
hypertension (PH) and ILD, respectively. For each of these measures, a value
above or below clinically established thresholds is a surrogate for these end-
points. The situation for managing scleroderma patients is common to many
other chronic diseases. Multiple measurements are observed on each organ
system, discrete events need to be identified, and measurements are highly
irregular in their distributions and observation times. By accurately estimating
an individual’s organ-specific trends using such data, we can explain how
the disease is evolving over time and also provide probabilities of the patient
having one or more critical events in the near future. Additionally, we can
potentially add value to patient care by fitting models that jointly estimate
disease trajectories for several organs. It should be noted that, in this study,
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the events of interest are solely determined by the values of continuous mea-
surements. In other words, the clinical events of interest are the biomarkers
themselves crossing a threshold. For cases where the events are not direct
functionals of continuous observations (for example, death or renal crisis of
scleroderma patients), jointly modeling longitudinal and time-to-event data to
predict the risk of having an event given longitudinal profiles are widely used.
The joint model proposed by Faucett and Thomas, 1996 and Wulfsohn and
Tsiatis, 1997 are considered as the standard models, and several extensions
were proposed to accommodate multivariate longitudinal profiles. Xu and
Zeger, 2001 used a multivariate mixed model framework to model multiple
continuous surrogate markers to evaluate treatment effect in a schizophre-
nia trial and proposed a measure to quantify the relative benefits of using
multiple surrogates. Rizopoulos and Ghosh, 2011 proposed a semiparametric
multivariate joint model to model 3 longitudinal outcomes time to renal graft
failure. Other applications are presented by Brown, Ibrahim, and DeGruttola,
2005, Proust-Lima and Taylor, 2009, and Garre et al., 2008.
In the following sections, we introduce and fit multivariate models to
estimate individual’s risk of the critical events that serve as surrogates of
cardiomyopathy, PH, and ILD. Similar to the models mentioned above, we
will jointly fit a model with multiple longitudinal outcomes of interest. We
expect better performance of this joint model as the model will borrow strength
from the observations in other markers in predicting risk in less frequently
measured markers. We compare the precision of our multivariate model to a
series of models that use the events themselves as the outcome and takes the
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individuals’ past trajectory as predictor variables. We further investigate the
gains in precision by fitting our multivariate model in different situations, i.e.
where outcome measures are highly correlated compared to the case where
they are not. Finally, we present our approach to checking the violation of the
normality assumptions of the multivariate models and tests to check the need
of model calibration.
3.2 Methods
3.2.1 Modeling multivariate measures and events
Motivated by the scleroderma case study, we propose to develop methodology
to infer individual and population etiologies by fitting Bayesian multivariate
hierarchical models introduced in Chapter 2 that describe the relationship
between an individual’s disease trajectory as reflected in the combination of
sentinel events and longitudinal measures.
In Figure 3.1, ηi represents the time-varying disease state of patient i that
is reflected in a vector of observations Yi and events Ei. The underlying health
state ηi are measured with measurement error ϵi whose covariance is Ση,Y. At
any given time t, the observed covariates including baseline measurements
Xi such as autoantibody status and cutaneous subtypes cause the disease
trajectory status ηi as quantified by regression coefficients βη,X. Population-
level estimates βη,X combined with an individual’s random deviation from
the population average bi fully describes the individual’s trajectory at any
given time.
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Figure 3.1: Diagram describing etiology of disease progression of an organ reflected
in a single biomarker
The model can capture the disease state in multiple organs by jointly
fitting all biomarkers in a single model at once. Univariate analyses in which
each outcome measure or event is considered on its own are more popular
largely because modeling a single outcome, even several times, is much easier
than modeling them jointly. However, in such models, the across-measure
associations in the random effects and residual errors are ignored. Failure to
account for these associations results in less efficient estimators particularly in
the presence of high measure-wise correlations as shown in Chapter 2.
3.2.2 Multivariate outcome models
In this section, we define the longitudinal measurements and clinical events
used for this study. We use clinical data in the Johns Hopkins Scleroderma Cen-
ter Research Registry. Longitudinal data of the biomarkers ejection fraction
(EF), right ventricular systolic pressure (RVSP), percent predicted forced vital
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capacity (FVC), and percent predicted diffusing capacity of carbon monoxide
(DLCO) are used to describe the disease trajectory of patients who have at
least 3 observations for each of the measures. Onset of the disease is defined
as the earlier of the onset of Raynaud’s phenomenon and first non-Raynaud’s
symptom. We restrict our analysis to data collected between 0 to 40 years since
onset. Clinicians define thresholds for EF, RVSP, and FVC events below which
the patient is said to experience: cardiomyopathy, pulmonary hypertension
(PH), and interstitial lung disease (ILD), respectively. We use the following
two thresholds for each measure to differentiate between mild and severe
events:
EEF = I{EF < 50} and I{EF < 35}
ERVSP = I{RVSP ≥ 45} and I{RVSP ≥ 50}
EpFVC = I{pFVC ≤ 70} and I{pFVC ≤ 60}
From the empirical correlation matrices in Figure 3.2, we observe that
RVSP observations are generally highly correlated with DLCO and FVC,
while EF is not. We compare the performance of the predictors p(EpFVC)
from two models to assess benefit gained by jointly modeling more highly
correlated variables. We fit two multivariate linear mixed models each with
three longitudinal outcomes. The first model uses pFVC, pDLCO, and EF, and
the second model uses pFVC, pDLCO, and RVSP. For any patient at a given
moment in the future, p(EEF) and p(EFVC) can be calculated from the first
model, and p(ERVSP) and p(EFVC) from the second.
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Figure 3.2: Empirical correlation matrix of the preprocessed variables
For each outcome measure, we select a set of predictors (covariates) for
the fixed effects. The common predictors across all outcomes are age of
scleroderma onset, race, gender, skin subtype, and autoantibody status for
the 3 most common scleroderma specificities (ACA, RNAPol and Scl-70). To
model changes in patients’ health trajectories in time since onset, we also
include a smooth function of time using natural splines with 3 degrees of
freedom where internal knots are placed at 10 and 30 years since onset, and
boundary knots at 0 and 40 years since onset. Note that the set of common
variables are allowed to have different coefficients for each measure. Measure-
specific regression predictors and coefficients are essential to describe the
state of a patient’s scleroderma, as it is known that each clinical subtype
is at different risks for organ complications (Shah and Wigley, 2013). For
example, patients with limited skin type are at higher risk of developing PH
but lower risk of developing ILD (Schoenfeld and Castelino, 2015; Legendre
and Mouthon, 2014).
For patient-specific random effects, we fit a random slope and intercept
and two linear splines at 3 and 10 years from the last observation. The same
53
set of variables are used as random effects for all outcome variables. Covariate
estimates for the two spline terms represent additional rate of change in a
patient’s trajectory in the last 10 years and then last 3 years. These terms are
introduced to capture the recent trend in the trajectory more accurately, by not
letting the observations measured early in the disease have excessive influence
on the recent trend.
3.2.3 Preprocessing of longitudinal data
Prior to analysis, all 4 outcome measures are preprocessed using quantile
normalization. Let Yk be a vector of the observed values from each measure
k = 1, ..., 4. The quantile normalized vector is obtained by Φ−1 ◦ Ĝk(Yk),
where Ĝk is an estimated distribution of the vector Yk and Φ−1 is the inverse
of the standard normal distribution. To calculate the quantile normalized
values, observations from each measure are sorted in ascending order, paired
with and then assigned the values of the corresponding percentiles from
standard normal distribution. Lastly, RVSP observations are transformed by
multiplying by -1 so that increase in all 4 measures indicates better health
status.
Thresholds for the three events are also transformed to the normalized
scale, which we will call cEF, cRVSP, and cpFVC. Also, note that each measure
is individually transformed to follow a standard normal distribution, but
this procedure does not guarantee joint normality of the random errors and
random effects of the 3 variables used in each model. In section 3.2.7, we
propose a simple method to check whether the joint normality assumption is
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seriously violated.
3.2.4 The multilevel response models and prediction
Let Yijk be the observed value for the kth measure for person i = 1, . . . , m at
the jth visit j = 1, . . . , nik, at time since onset tijk and, let Yik be the vector of
Yijk for j = 1, . . . , nik. Xik and Zik are (nik × pk) and (nik × qk) known matrices
of full rank, and βk and bik are pk × 1 and qk × 1 measure-specific vector of
parameters for fixed and random effects. Let ni = ∑Kk=1 nik and eik random
measure-specific within-subject error term.
In this application, we observe K = 3 with five different measures.










Each linear mixed effects model is written as
Yi = Xiβ + Zibi + ei, i = 1, ..., m
where
β = (βT1 , ..., β
T
K)











bi = (bTi1, ..., b
T
iK)
T ind∼ NKq(0, D)
ei = (eTi1, ..., e
T
iK)
T ind∼ Nni(0, Σi).
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Let Yij+ be the K × 1 vector of patient i’s health state at an unobserved
time tij+. Future observations Yij+ satisfy the model assumption
Yij+ = Xij+β + Zij+bi, i = 1, ..., m
where Xij+k and Zij+k are (1× pk) and (1× qk), and Xij+ =
⨁︁K
k=1 Xij+k, Zij+ =⨁︁K
k=1 Zij+k. The random errors eij+
ind∼ NK(0, Σij+). To predict the probability
of clinical events at tijk, we use the conditional distribution of Yi+ given Yi.
Here, Yi is the vector of outcomes of patient i observed until tijk. The joint















where Vi = ZiDZTi + Σi, Vij+ = Zij+DZ
T
ij+ + Σij+, and Cij+ = ZiDZ
T
ij+
Hence, Yij+|Yi = yi ∼ N
(︁
E(Yij+|Yi = yi), Var(Yij+|Yi = yi)
)︁
and
E(Yij+|Yi = yi) = Xij+β + CTij+V−1i (yi − Xiβ)
Var(Yij+|Yi = yi) = Vij+ − CTij+V−1i Cij+
When no outcome is observed before tijk , E(Yij+|Yi = yi) and Var(Yij+|Yi =
yi) reduce to E(Yij+) = Xij+β and Var(Yij+) = Vij+. We can obtain a set of
probabilities at tijk, by calculating the probability of the conditional distribu-
tions falling below cEF, cRVSP, and cpFVC.
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From model 1,
P(EEF,ij+) = Φ(cEF, E(Yij+3|Yi = yi), Var(Yij+3|Yi = yi))
P(EpFVC,ij+) = Φ(cpFVC, E(Yij+1|Yi = yi), Var(Yij+1|Yi = yi))
From model 2,
P(ERVSP,ij+) = Φ(cRVSP, E(Yij+3|Yi = yi), Var(Yij+3|Yi = yi))
P(EpFVC,ij+) = Φ(cpFVC, E(Yij+1|Yi = yi), Var(Yij+1|Yi = yi))
where Φ(x, µ, σ2) is a normal density function with mean µ and variance
σ2.
3.2.5 Bayesian inference
The probabilities given in the previous section are just functionals on the
parameters of the multivariate mixed effects model. We estimate the posterior
distribution of the model parameters and of our functionals of interest using
a Bayesian inference framework. We fit models 1 and 2 using an R package
MCMCglmm (Hadfield, 2010) and obtain posterior distributions of all pa-
rameters of interest from Markov Chain Monte Carlo (MCMC) chains. For
the fixed effects of both models, we use a diffuse independent normal prior
centred around zero with a large variance of 108. Weakly informative inverse-
Wishart priors are placed on random effects and residual covariance matrices.
Based upon prior medical knowledge, we set the prior distribution of the
random intercepts to have mode equal to one and random slopes and linear
spline terms to have the mode equal to 0.005, with 12 degrees of freedom. The
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prior distribution of the residual covariance matrix takes the mode of 1 for
each measure, with 3 degrees of freedom. The degrees of freedom are chosen
to make the distributions as diffuse as possible while guaranteeing them to be
valid inverse-Wishart distributions. Scale matrices for both distributions are
calculated using the chosen degrees of freedom and modal values.
3.2.6 Cross-validated sequential prediction (CVSP) for mul-
tivariate longitudinal data (MLD)
The model described above yields the predicted probability of having an event
for any unobserved outcome measured at tijk. We want to compare to our
predictions with the observed rates of events. For each patient i, we could
naively use all observed data Yi until tijk and untruncated data of all other
patients but doing so requires fitting the models m × nik × K since observation
times for the different measures are irregular. Refitting the models whenever
a new data point is collected is extremely inefficient especially in a clinical
setting.
One way to circumvent this problem is to calculate E(Yij+|Yi = yi) and
Var(Yij+|Yi = yi) using D̂ and Σ̂i estimated from a pool of patients’ excluding
patient i. Once posterior means for D̂ and Σ̂i are obtained, V̂i, V̂ij+, Ĉij+, and
β̂ are easily calculated as they are functionals of D and Σi. As we sequentially
move from ti1k to tinikk, we generate time-varying Xij+ and Zij+ and obtain the
predicted event probabilities for all ni time points with pre-estimated D̂ and
Σ̂i. This approach, which we will call Cross-validated Sequential Prediction
(CVSP for MLD) is also used to assess model precision. We perform 5-fold
cross-validation by dividing all patients into 5 groups. 5 sets of D̂ and Σ̂i
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are estimated using 80% of the data not in the selected fold, and P̂(EEF,ij+),
P̂(ERVSP,ij+), and two P̂(EpFVC,ij+) are calculated for all ∑i ni measurements
for the patients in the selected fold. Finally, we calculate and compare the
cross-validated AUC (CV-AUC) of the 4 estimated event probabilities.
3.2.7 Checking of joint normality assumption
Although the outcome variables are quantile normalized individually, there
is no guarantee that the normalized outcomes follow a multivariate normal
distribution. As our prediction models depend on the joint normality assump-
tion of the random effects and random errors, we need to check whether this
assumption is reasonable, and when it is not, have a method to calibrate the
predictions to better match the cross-validated observed rates of events. Here,
we first introduce a method of checking systematic or extreme departures
that may affect the performances of prediction by examining the marginal
residuals from models 1 and 2 described in 3.2.2.
Recall the notation
Y = (YT1 , ..., Y
T
m)







b = (bT1 , ...b
T
m)
T, e = (eT1 , ...e
T
m)






so that our joint model has the simple form
Y = Xβ + Zb + e
where Y ∼ N(Xβ, V), V = ZΓZT + Σ, b ∼ N(0, Γ), e ∼ N(0, Σ).
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With known β, the residuals from the linear regression models Y − Xβ =
Zb + e which is normal with mean 0 and covariance matrix V. We exam-
ine the normality of scaled residuals of each measure by calculating U =
diag(V̂)−1/2(Y − Xβ̂) which should be samples of standardized normal. We
examine the Q-Q plots for each measure where the standardized residuals are
plotted against the standard normal and look for obvious departures of the
points from the 45 degree line.
3.2.8 Empirical prediction models
In order to compare the performance of our proposed approach implemented
using CVSP, we propose alternative, simpler prediction methods using logistic
regressions. We build a set of models to predict EF events and then another
set for RVSP. The three models LM1, LM2, and LM3 are defined as follows:
LM1 : logit(Eij+) = ns(Yprev1, ν) + Yij,pFVC + Yij,pDLCO + common covariates
LM2 : logit(Eij+) = ns(Yprev1, ν) + ns(Yprev2, ν) + Yij,pFVC + Yij,pDLCO
+ common covariates
LM3 : logit(Eij+) = ∑
j<j+
Eij + ns(Yprev1, ν) + ns(Yprev2, ν) + Yij,pFVC + Yij,pDLCO
+ common covariates.
Here, logit(Eij+) is the logarithm of the odds of having an EF or RVSP event
at time j+ for patient i. As we are not directly modeling the latent trajectory
as we did in the two models described in Section 3.2.4, we sequentially add
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covariates that can summarize past trajectories in multiple measures. Yprev1
and Yprev2 are the most recent and second to the most recent observations
of EF or RVSP prior to j+ for patient i. We fit a smooth function of Yprev1
and Yprev2 using natural splines with ν = 2 degrees of freedom. Yij,pFVC and
Yij,pDLCO are patient i’s most recent observations of pFVC and pDLCO prior to
j+. ∑j<j+ Eij is the counts of EF or RVSP events in the past for patient i before
j+. We expect the additional information of past trajectory reflected in Yprev2
and ∑j<j+ Eij to result in improved prediction. The common covariates are
identical to those in Section 3.2.4. For each of the two outcomes, we calculate
CV-AUC from 5-fold cross-validation of the three models.
3.2.9 Calibration of CVSP for MLD
We check if calibration is needed for our models by examining predicted prob-
abilities of 6 events. For each set of predicted probabilities, we compare the
estimated and observed cases within quintiles of the predicted probabilities.
We perform chi-square goodness of fit tests to test whether the estimated
number of cases matches the cases we observe across the quintiles. If we fail to
reject the null, indicating a discrepancy between the estimated and observed
probabilities, then we calibrate the model using the logistic regression of the
observed cases against a smooth function of predicted values.
3.3 Results
Table 3.1 shows the number of patients whose data are used in model 1 and
2 and the number of events occurred. There are 577 patients with more than
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3 observations for EF, pFVC, and pDLCO and 459 patients with more than
3 observations for RVSP, pFVC, and pDLCO. EF events are rarer than RVSP
events; FVC events are the most common.
Model 1 n EF < 50 EF < 35 pFVC ≤ 70 pFVC ≤ 60
577 173 36 2215 1183
Model 2 n RVSP ≥ 45 RVSP ≥ 50 pFVC ≤ 70 pFVC ≤ 60
459 381 240 1891 995
Table 3.1: Number of patients and events used in model 1 and model 2
We first performed a series of Chi-square goodness of fit tests using the
observed and expected cases in the quintiles of predicted probabilities for each
event from all proposed models. Tables 3.2 and 3.3 present the Chi-square
statistics and p-values. For all models and events, we failed to reject the
null hypothesis that there is statistically significant difference between the
observed counts and expected counts of events estimated from the models.
Hence, we proceed without calibration of the predicted probabilities and
compare the precision of the proposed models.
CVSP LM1 LM2 LM3
EF < 50 6.74 (p = 0.76) 13.51 (p = 0.98) 13.41 (p = 0.98) 6.31 (p = 0.72)
EF < 35 9.49 (p = 0.91) 31.44 (p = 1.00) 18.52 (p = 1.00) 10.51 (p = 0.94)
RVSP ≥ 45 6.33 (p = 0.72) 7.5 (p = 0.81) 7.8 (p = 0.83) 1.57 (p = 0.09)
RVSP ≥ 50 9.05 (p = 0.89) 8.71 (p = 0.88) 11.36 (p = 0.96) 3.17 (p = 0.33)
Table 3.2: Results from Chi-square goodness of fit test of the proposed models
CVSP from model 1 CVSP from model 2
FVC ≤ 70 97.16 (p = 1.00) 120.89 (p = 1.00)
FVC ≤ 60 13.34 (p = 0.98) 11.55 (p = 0.96)
Table 3.3: Results from Chi-square goodness of fit test of CVSP from model 1 and 2
62
Table 3.4 presents the CV-AUC for the two EF events and two RVSP pre-
dicted by the CVSP and three empirical methods. For the three empirical
methods, we observe that sequentially adding covariates that summarizes
individuals’ past history results in improved or similar (comparing AUC for
LM1 and LM2 in predicting EF < 35) prediction. The CVSP yields the highest
CV-AUC in predicting all events. Comparing within the EF and RVSP events,
the CVSP demonstrates better performance for stricter thresholds (EF < 35
and RVSP ≥ 50) whereas the three empirical methods show similar precision.
The result suggests that the CVSP may be useful in predicting other rare
clinical events.
CVSP LM1 LM2 LM3
EF < 50 0.822 (0.785-0.858) 0.762 (0.660-0.864) 0.779 (0.682-0.876) 0.788 (0.693-0.862)
EF < 35 0.830 (0.752-0.909) 0.772 (0.729-0.816) 0.771 (0.728-0.815) 0.794 (0.755-0.836)
RVSP ≥ 45 0.855 (0.835-0.875) 0.790 (0.764-0.817) 0.798 (0.772-0.824) 0.811 (0.786-0.837)
RVSP ≥ 50 0.872 (0.848-0.895) 0.796 (0.762-0.829) 0.802 (0.769-0.835) 0.817 (0.785-0.848)
Table 3.4: Cross-validated AUC and 95% CI of 4 critical events by proposed methods
There is only minimal difference of the two models in predicting pFVC
events using CVSP. For pFVC ≤ 70, CV-AUC is 0.956 (95% CI: 0.951-0.961) for
model 1 and 0.955 (95% CI: 0.950-0.960) for model 2. For pFVC ≤ 60, CV-AUC
is 0.961 (95% CI: 0.956-0.967) for model 1 and 0.960 (95% CI: 0.954-0.966) for
model 2. The two models performing equally well implies that the estimated
pFVC trajectory coupled with that of pDLCO are highly predictive of the
pFVC events. The trend is captured in Figure 3.2, where we can observe
highly correlated pFVC measurements across time within individuals unlike
EF or RVSP. It is likely that jointly modeling pFVC and pDLCO leaving out
the cardiac measurements can also produce a highly predictive model.
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Figure 3.3: Cross-validated AUC by the number of EF observations. nEFi indicates the
number of EF measurements observed for individual i prior to making a prediction.
Figure 3.3 shows how much the CVSP for MLD improves over time as more
data are observed. The CV-AUC improves from 0.721 to 0.906 as the number
of the observed EF measurements increase from 0 to over 2, suggesting that the
more data a patient has, the better precision is expected. However, even in the
case of no previous observations, the CVSP has decent precision, illustrating
that patients’ demographic and clincal subtype along with their estimated
pFVC and pDLCO trajectories provide reasonable prediction of their future
EF trajectory.
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Figure 3.4: Normal Q-Q Plots
Finally, Figure 3.4 shows the Q-Q plots of the standardized residuals
against the standard normal. The three plots on the top row show the sample
quantiles of each of the measures in model 1 against quantiles of standard
normal, and the three plots on the bottom row show those from model 2.
We conclude that there are no major departures in the distributions of the
scaled residuals from normality that can significantly compromise the CVSP
predictions as the results above confirm.
3.4 Discussion
We introduced Bayesian multivariate hierarchical models to quantify an in-
dividual’s risk of multiple important clinical events. The events are defined
by clinicians to be the crossing of a biomarker threshold. So there is potential
advantage to modeling the multivariate biomarkers themselves, and then
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use the model to predict the crossings. We demonstrated that this approach
does produce predictions with substantially higher precision as compared to
the traditional prediction models. We also showed that the proposed models
better separate patients when there is longer follow-up time, but we have
considerable precision even with shorter follow-up time. In this analysis, we
focused on the marginal risk of individual events, but we can easily obtain
the joint predicted probabilities of multiple events and estimates of other
quantities of interest from the models’ joint posterior distributions.
For scleroderma patients, cardiomyopathy, PH, and ILD are events with
high morbidity and mortality, and timely risk predictions are essential because
they: (1) warn clinicians of higher risk in need of increased monitoring and
interventions; (2) reduce concerns in patients at lower risk. The method
of multivariate sequential updating of predictive distributions has broad
application in the clinical setting. The method can be easily implemented
as it provides individualized latent disease trajectories and risks of future
events in multiple organs as patients’ new data are observed without requiring
refitting the prediction models. To use CVSP for MLD, we divided patients
into K = 5 folds of data. To obtain predictions for a patient in the kth fold, we
produce estimates of the random error and random effects covariance matrices
leaving out the kth fold. In this way the estimated matrices by construction
are independent of the left out data. We then use the fixed and random
effect estimates which are functionals of the estimated covariance matrices
to sequentially estimate a patient’s risk of events given only the past data.
Although we demonstrated our approach with an application to scleroderma,
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it has broader application to other complex diseases that require multiple
measures to monitor progression.
We check the normality assumptions of random effects and random error
terms to see if the assumptions are seriously violated by investigating the
scaled residuals. For our particular data, we did not observe any major depar-
ture in the distributions of the residuals from normality. We also confirmed
that there was no obvious need to perform calibrations of the prediction mod-
els from a series of chi-square goodness of fit tests. However, in order for
our models to be clinically used, it is important to thorough rigorous variable
selection and model validation. We have selected the common covariates that
are known to influence these outcome variables based on clinical knowledge,
but the model allows independent fixed and random effects for each outcome
variable including time-varying covariates. There are other modeling choices
such as more informative prior distributions or alternative covariance struc-
ture specification for random errors and random effects that also needs to be
investigated to improve our proposed models.
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Chapter 4
Patient interface design and
evaluation
4.1 Background and Significance
Systemic sclerosis is a complex autoimmune rheumatic condition that can
involve multiple organ systems (skin, peripheral vasculature, heart, lung, kid-
neys, muscles, joints, etc). It is standard of care to assess these multiple organ
systems separately – for instance, by capturing measures of skin thickness,
distribution and extent (the modified Rodnan skin score or mRSS), Raynaud’s
phenomenon severity (digital pitting scars, ulcerations, and gangrene), left
and right ventricular function and estimated pulmonary arterial pressures
from echocardiograms, and forced vital capacity and diffusing capacity mea-
surements from pulmonary function tests. Medical decision making is quite
challenging because it requires integrating information across multiple param-
eters and organ systems, factoring in a patient’s prior trajectory and baseline
risk factors, and deciding whether a therapeutic intervention is warranted and
if so, what is the optimal treatment. Aggregating this complex, longitudinal
68
data for clinical use prior to clinic visits requires a tremendous time invest-
ment on the part of the treating physician. It is also challenging to clearly
explain this information to patients during a routine clinical visit to facilitate
shared decision making. Lastly, because scleroderma is a complex and rare
disease, it is often difficult to address questions of importance to patients, such
as: what is the current status of my disease; what is my future likely to hold;
and how do I compare with other scleroderma patients?
Modern statistical methods discussed in prior chapters can use multivari-
ate, longitudinal measures to address patient’s questions. To do so, we must
design, implement and test an interactive interface to communicate visual-
izations of a patient’s and reference population’s longitudinal data. The first
step is to construct a web-based application that estimates and communicates
a person’s likely disease status, past trajectory, and predictions of what is
expected in the coming period. Then, to improve clinical practice, it must
be tested in our clinics, and finally implemented within the workflow of the
health systems that use it.
In this study, we present the design of our data visualization tools and
propose a clinical trial to test their efficacy. Specifically, the trial will address
two questions:
• In comparison to the distribution of states and trajectories for a reference
scleroderma population, does visualization of a patient’s individual
disease state and trajectory improve patient satisfaction and comfort
with medical decision making, and reduce decisional regret?
• Does access to a patient level data visualization model improve the
69
efficiency of care, in terms of data capture, delivery of information to
patients, and physician satisfaction?
Once our visualization tools are implemented at Johns Hopkins and ap-
proved for wider use based upon the clinical trial designed here, we will
enhance the tool by including predictions of future trajectories and the risks
of organ-specific complications as described in the previous chapter. We will
use a similar protocol to test the utility of the enhancements. We will then
seek to disseminate this tool beyond Johns Hopkins for broader use in the
rheumatology community.
4.2 Methods
4.2.1 The Johns Hopkins Scleroderma Center Research Reg-
istry
This study will use clinical data in the Johns Hopkins Scleroderma Center
Research Registry, that is a university supported Precision Medicine Center of
Excellence (PMCOE). The Center includes all patients who meet classification
criteria for systemic sclerosis (SSc, scleroderma) who are seen at the Johns
Hopkins Scleroderma Center or are inpatients at Johns Hopkins hospitals. The
Center has created and maintains a large longitudinal database and bioreposi-
tory (serum, plasma, DNA, RNA, peripheral blood mononuclear cells; tissue
bank: skin, cancer, heart, lung, kidney, GI and other body tissue) of patients
with scleroderma and other autoimmune diseases, along with appropriate
controls. This is a dynamic entry registry with ongoing enrollment.
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Figure 4.1: Data flow in the Johns Hopkins Precision Medicine Analytics Platform
(PMAP)
Data from center participants have been ingested into the Johns Hopkins
Precision Medicine Analytics Platform (PMAP). PMAP is an information tech-
nology component of the "Hopkins inHealth" Precision Medicine Program
designed to enable learning within the practice of medicine. The Epic elec-
tronic health record at Johns Hopkins Medicine captures all transactions that
comprise clinical care: clinical visits (history and examination, vital signs),
laboratory measurements, prescriptions, procedures, and much more. Each
evening, the main Epic data tables from the past 24 hours are copied to PMAP,
an Azure cloud-based system for integrating and analyzing patient data from
multiple sources. The major goal of Hopkins inHealth is to use modern mea-
surement, data science, and connectivity tools to discover clinically relevant
subgroups at scale and to deliver what we learn to impact the precision and
value of health care. This study, a component of Hopkins inHealth, uses the
nightly-updated data from PMAP as input to our patient-level data visualiza-
tions and predictions.
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4.2.2 Steps to improve patient care
4.2.2.1 Approach
In the current practice of medicine, a clinician has access to historical and
current data only about the patient at hand. That information is not typically
organized or presented in a fashion for the clinician to appreciate the current
status relative to its past. In addition, the patient’s data are not placed within
the context of other similar patients. For example outcomes for prior similar
patients are not typically available. Clinicians therefore are forced to make
qualitative judgements about the patient’s status, trajectory, and likely benefits
of different treatments, not fully informed by either the patient’s own data or
the experiences for other similar patients.
To improve patient care, this project takes the first steps towards:
• synthesizing and visualizing all of the historical and current data about
a patient for clinician and patient use
• picturing the patient’s current status and trajectory within the context of
similar data for a user-specified sub-population of patients.
4.2.2.2 Delivering information to clinicians and patients
In order to improve patient care, a data science tool must ultimately be embed-
ded within the clinical workflow used by physicians to guide their interaction
with patients. We have already reached this end goal for a part of the work de-
scribed here. Our visualization and analysis (VA) tool was initially developed
in prototype form as an R Shiny application (App) (Chang et al., 2020). R Shiny
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is a package that builds interactive web apps from R (R Core Team, 2020).
Expert clinicians selected the key clinical information to be displayed. They
reviewed and approved preliminary versions of all displays. As the next step,
The Johns Hopkins Medicine Technology Innovation Center (TIC) used our R
Shiny VA to implement within Epic, the JHM electronic health record, a ver-
sion of our tool that physicians can directly use to test its value in clinical care.
The TIC used the first clinician-approved version of part of our VA to build an
Epic version called "Patient InSight". That version will be replaced by updated
versions that incorporate estimation of patient trajectories, predictions of fu-
ture trajectories and major events, and likely benefits of treatment options,
once approved for clinical use. At the moment, the dynamic estimation and
prediction of individuals’ disease state and trajectory is only developed in
the R Shiny app but will soon be embedded in the web-based VA. The final
step necessary to improve patient care is to scale the use of the tool across
all scleroderma and similar autoimmune disease patients at Johns Hopkins
and beyond. That will require investment of a production scale version of the
app by the Chief Medical Information Officer who prioritizes this app against
others. Dissemination beyond JHM will be the domain of Johns Hopkins
Technology Ventures. Our work is regularly shared with both of those offices
so they are kept appraised of tool improvements in development.
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4.2.3 Clinical data visualization
The VA illustrates a patient’s aggregate clinical phenotype in a snapshot view,
including cumulative disease manifestations, disease onset dates and autoan-
tibody status. Any history of the following features are listed as disease
manifestations: interstitial lung disease, pulmonary arterial hypertension,
renal crisis, tendon friction rubs (TFRs), synovitis, myopathy, calcinosis, and
other components of the 2013 American College of Rheumatology classifica-
tion criteria for SSc (van den Hoogen et al., 2013). Comorbid conditions such
as peripheral artery disease (PAD), coronary artery disease (CAD), atheroscle-
rotic cardiovascular disease (ASCVD), hypertension (HTN), and cancer are
also captured.
Longitudinal data are illustrated across multiple organ systems includ-
ing: 1) cardiac (left ventricular ejection fraction (EF), right ventricular systolic
pressure (RVSP), and right heart catheterization data), 2) pulmonary (percent
predicted forced vital capacity – pFVC and diffusing capacity – pDLCO), 3) cu-
taneous (modified Rodnan skin score – mRSS), 4) gastrointestinal (Medsger GI
severity scores relative to body mass index), 5) peripheral vasculature (Meds-
ger Raynaud’s scores capturing damage including digital pits, ulcerations and
gangrene), and 6) muscle (proximal muscle strength on a 0-5 scale).
Additionally, we incorporated longitudinal body mass index (BMI), patient
reported Health Assessment Questionnaire (HAQ) Disability Index (DI), organ
involvement characterized by critical events, medications, additional labo-
ratory data, and a summary of cardiopulmonary comorbid conditions. Lon-
gitudinal immunosuppressive medication exposure data is shown to assess
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whether drug exposure alters trajectory in cutaneous and pulmonary parame-
ters. Critical events are defined as longitudinal observations in multiple organs
exceeding or falling below pre-specified thresholds. We indicate events for
heart (EF < 50), PH (RVSP ≥ 45 and mean pulmonary arterial pressure (PAP) ≥
25 for patients with right heart catheterization (RHC) data), lung (pFVC < 70
or pFVC < 60 and maximum mean PAP < 25 for patients with RHC), muscle
(severity score of 4), GI (severity score of 4), and renal crisis by plotting them
on a single time scale starting from scleroderma onset.
4.2.4 Estimation of disease state
4.2.4.1 Comparing individuals’ trajectory to a user-defined subgroup
The tool incorporates the 10th, 50th and 90th percentile values for the entire
Hopkins scleroderma cohort as a reference group for the pulmonary and
cutaneous trajectories in particular. By plotting individuals’ trajectories on
top of the three reference lines, we get a better sense of patients’ disease pro-
gression compared to others in their cohort. Moreover, we compare patients’
trajectory to a user-specified subgroup based on clinical and demographic
characteristics. This makes it easier for clinicians and patients to monitor their
disease progression relative to a group of similar patients based upon known
risk factors. In this application, we provide the group-specific quantile lines
by filtering patients based on their biological sex, range for reference age of
scleroderma onset, race, cutaneous subtype, and autoantibody status (positive
for ACA, Scl-70, and RNAPol, or any combinations thereof).
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4.2.4.2 Estimation of individuals’ disease state and trajectory
A patient’s true disease state or trajectory is an unobserved construct reflected
in their longitudinal measurements and occurrences of sentinel events. We
recognize that the disease status in multiple organs is measured longitudinally
with error and often times missing. We use a tool that effectively estimates
patients’ disease state and rate of progression at any given moment and then
communicate the estimates by integrating them within the visualization app.
By fully utilizing information in multiple longitudinal markers, we maximize
the efficiency of estimates of patient-specific and population trajectories.
We model the latent health state for lung function measured pFVC and
pDLCO, heart function measured by RVSP and EF, and skin involvement mea-
sured by mRSS since individuals’ disease onset. As is the clinical tradition,
disease onset is defined by the earlier of the onset of Raynaud’s phenomenon
and first non-Raynaud’s symptom. Prior to analysis, all 5 outcome measures
are preprocessed using quantile normalization. Let Yk be a vector of the
observed values from each measure k = 1, ..., 5. Conceptually, the quantile
normalized vector for each k is obtained by Φ̂−1 ◦ Ĝk(Yk), where Ĝk is an
estimated distribution of the vector Yk and Φ̂
−1 is the inverse of the standard
normal distribution. Lastly, RVSP and mRSS observations are transformed
by multiplying -1 so that increase/decrease in all 5 measures indicates bet-
ter/worse health status.
We fit a Bayesian multivariate linear mixed effects model (MLMM) that
accommodates the nested structure of the data: measures within time within
a patient within a population. For each outcome measure, we select a set
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of regression predictors (covariates) for the fixed effects. Here, we use age
of onset, race, biological sex, cutaneous subtype, and indicators of positive
ACA, RNAPol and Scl-70 antibodies. To model changes in patients’ disease
trajectories in time since onset, we also include a smooth function of time
using natural splines with a degrees of freedom chosen based upon prior
knowledge about over what time scale the disease state changes. Here we use
3 degrees of freedom in order to focus on the longer-term changes that are of
greatest clinical relevance. The internal knots are placed at 10 and 30 years
since onset; boundary knots at 0 and 40 years since onset. For patient specific
random effects, we fit a random slope and intercept and two linear splines at
3 and 10 years from the last observation.
We fit the model using an R package MCMCglmm (Hadfield, 2010). For
the fixed effects of both models, we use a diffuse independent normal prior
centered around zero with a large variance (108). Weakly informative inverse-
Wishart priors are placed on random effects and residual covariance matrices.
Based upon prior knowledge of heterogeneity among patients, we set the prior
distribution of the random intercepts to have mode one and random slopes
to have mode of 0.005, with 20 degrees of freedom. The prior distribution
of the residual covariance matrix is assumed to have the mode one for each
measure, with 5 degrees of freedom. The degrees of freedom are chosen to
make the distributions as diffuse as possible while guaranteeing them to be
proper inverse-Wishart distributions.
Using the estimates from the model, we obtain and plot disease trajectories
for each patient for the clinically selected measures pFVC, RVSP, and EF. These
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were chosen because they are most important for treatment decisions and
because the registry has a sizeable sample of people with long histories for
these variables. Note that the estimated trajectories are transformed back to
the original scales in the VA in R Shiny App for better communication of the
results.
4.2.4.3 Prediction of future risk of critical events
The estimated level and the trend of a patient’s disease trajectories serve as
an indicator of the risk of having extreme values of biomarkers in the near
future. Although estimated smooth trajectories in multiple organs describes
how individuals’ scleroderma evolved over time, the presence or absence
of extreme values in patients’ longitudinal observations is also clinically im-
portant. Observations falling below or rising above a clinically set threshold
often serve as surrogates for critical events, and such events require immedi-
ate medical attention sometimes followed by more invasive and higher risk
interventions. For example, EF ≤ 35 implies severe heart failure and patients
are often treated with implantable cardioverter defibrillator (ICD) placement.
We extend the work in Section 4.2.4.1 by projecting individuals’ health tra-
jectory into the future, to predict their risk of having critical events defined as
following: EF < 50 and EF < 35 (cardiomyopathy), RVSP ≥ 45 and RVSP ≥
50 (PH), and pFVC ≤ 70 and pFVC ≤ 60 (ILD). For each patient, we calculate
the probability of having each of the events in the next 6, 12, and 18 months
from the most recent visit using the Cross-validated Sequential Prediction
(CVSP) using Multivariate Longitudinal Data (MLD) method. For details of
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the CVSP method, see Chapter 3.
4.2.5 Evaluation of value added
We propose to study the value of this tool in the clinic by conducting a qualita-
tive research study using human factors analytic strategies and a randomized
clinical trial. In this paper, we introduce a way of efficiently using available
resources to assess whether a patient level, longitudinal data visualization
deployed in the scleroderma center clinic improves efficiency of care, patients
understanding of their disease, and shared medical decision making by:
• improving the efficiency of care in terms of data capture,
• improving the efficiency of care in terms of delivery of information to
patients,
• improving physician satisfaction,
• improving patient satisfaction and comfort with decision making, and
• reducing patient decisional regret.
Our plan is to conduct this study in two phases: 1) to assess the usability of
the tool from the designer, provider and patient perspective, 2) to assess shared
decision making from the patient perspective. Scleroderma patients who have
previously consented to participate in our scleroderma center registry and
who have at least one year of data will be included, as will scleroderma center
providers. Detailed study procedures are described for each of these study
populations in section 4.3.5.
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4.3 Results
4.3.1 The Visualization Application
In Figure 4.2, we illustrate a patient’s aggregate clinical phenotype and longi-
tudinal data in a snapshot view. The selected tab shows the patient’s cardiac
data, which are EF and RVSP measurements over time. Regions indicating the
severity of disease state are indicated by red (severe) and pink (mild) for each
measure. Data from RHC are displayed for patients who had the procedure at
the bottom of the tab. Below the longitudinal display of two heart measures,
we show longitudinal display of any immunosuppressive medication used by
the patient over time. The same plot of medications is also displayed in the
lung and skin tab so that the medication history can be in the same view with
the patient’s longitudinal data of lung or skin.
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Figure 4.2: A patient’s longitudinal observations. Users can view values for each
points by hovering over the points in the graphs.
In the medication plot, the colors and connections between the points
represent the patterns of medication exposure. Black points indicate that the
patient is currently on medication, green indicates the patient is currently not
on medication, but was on medication less than 6 months prior to visit. Grey
points indicate the patient is not on medication and the lines are connecting
black and green points if less than 15 months apart. Such method is employed
to extrapolate the true medication exposure of the patients. The method is
informative in that it separates missing medication data (no point plotted)
from no exposure (grey), prior exposure only (green), and current exposure
(black).
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4.3.2 Trajectory within a reference population
In this section, we demonstrate the utility of presenting an individual patient’s
data relative to specific subgroup characteristics. In figure 4.3, the trajectory of
a white woman who developed diffuse scleroderma with anti-topoisomerase
1 (Scl-70) antibodies with onset age of 40 years is compared to other patients
with similar demographic and clinical characteristics, providing insight into
how individual and combinations of risk factors may modify a patient’s likely
trajectory and outcome.
On the top panel (Figure 4.3 panel (a)), this patient’s trajectory is compared
with that of the overall scleroderma center cohort. On the bottom panel (panel
(b)), that same patient’s trajectory is compared with a reference population
that is similar to the patient (onset age of 30 to 50 years, diffuse type, Scl-70
antibody positive). These data illustrate how the reference population changes
the interpretation and one’s perspective. When comparing this patient to the
overall scleroderma population, we observe that her pFVC trajectory declines
from the 90th percentile to 10th over 20 years of follow up, dropping rapidly
below the 50th percentile line after 10 years. Relative to other similar patients,
however, we see that her pFVC trajectory is better than that typically expected
for the first 10 years of follow up and around the median afterwards.
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(a) Lung trajectories of a patient and 10th, median, and 90th percentiles reference
lines of the overall scleroderma population
(b) Lung trajectories of the same patient and 10th, median, and 90th percentiles
reference lines of selected subpopulation
Figure 4.3: Screenshots of the Lung tab of the R Shiny app
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4.3.3 The Web-based Visualization Application
In Figure 4.4, we present screenshots of the Epic-based visualization app called
Patient InSight that reproduces the interface of the VA created in R Shiny App
as demonstrated in previous sections. The information that displayed in each
tab in the R Shiny App are presented in a single page view that users can scroll
through. Users can select variables of interest to only view longitudinal data
of the selected variables. Filtering of the reference population and the 10th,
50th, and 90th percentile reference lines are also featured. The application is
currently used by physicians in the clinic mainly for the purpose of effectively
scanning through patient data to assess patients’ past and current health status
prior to patients’ visits. By implementing this version within Epic, we can
now conduct the clinical studies discussed below. This was not possible using
the Shiny app alone.
Figure 4.4: Screenshots of visualization assistance interface in Epic
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4.3.4 Estimating a patient’s risk of critical events
One feature that has not yet been implemented in the Epic-based VA is the
estimation of the latent disease trajectory across multiple organ systems and
the associated risk of critical events defined by specific thresholds. For each
patient, we estimate the underlying disease trajectory for pFVC, EF, and
RVSP through the most recent observation, and display them with the 95%
prediction interval. An example is shown in Figure 4.5. Note that the predicted
curves are obtained by jointly modeling the multiple measures. The method
is particularly useful when some measures have fewer data points observed
compared to others. In our case, patients generally have fewer observations
for cardiac measures (EF, RVSP) and richer data for the pulmonary measures
(pFVC, pDLCO). When there are only sparse data observed for a measure or
a patient, we borrow strength from the other measures and from the entire
cohort to produce more accurate and precise estimates.
In Figure 4.5, the estimated risk of 6 critical events (3 outcomes each with
2 severity levels) in the next 6 month are displayed. Projection time can be
switched to 12 or 18 months from the drop-down menu at the top. As the
events are directly defined by the value of the longitudinal measures, we
project the estimated trajectory forward in time and calculate the risk of the
future events using the estimated uncertainty around the prediction. The
areas of the shaded regions in the graphs (lighter and darker shades of green
and pink) indicate the estimated risk of having each event. The estimated risks
are also quantified and tabulated next to the graphs. This particular patient
has a high risk of having a clinically significant restrictive ventilatory defect
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(93% for pFVC ≤ 70) and only a slight chance of having cardiomyopathy or
PH (1% for EF < 50 and 3% for RVSP ≥ 45). The color coding is specific to the
measure throughout the app where blue represents the lung and red the heart.
Figure 4.5: Estimated trajectories and risks for an individual patient
4.3.5 Evaluation Study
4.3.5.1 Assessing the utility of the VA
In this section, we present a two-phase study design to evaluate the utility of
our visualization app.
Phase 1 - In this phase, the goal is to identify whether the VA improves the
communication of information to patients, patient satisfaction, and provider
satisfaction. We will first conduct semi-structured interviews for the 4 de-
signers of the visualization tool (2 physicians, 2 biostatisticians) to capture
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factors that influenced the design process. The tool will then be tested among
providers seeing patients in the scleroderma center. Baseline information
will be captured from study participants including age, sex, percentage of
clinical time, number of years since rheumatology training or year of training,
frequency of Epic EMR use, hours/week spent on a computer, computer
platform most often used (PC or Mac), and general comfort with technology.
Providers will also be asked how they typically prepare for seeing patients,
how much time goes into data collection, which variables providers tend to
share with patients, how they present evidence/data to patients, what infor-
mation they would find valuable to have access to quickly, and to what extent
they like making decisions independently vs with the input of their patients.
After these interviews are conducted, providers will have a session intro-
ducing them to the visualization tool, and how filters may be used to alter the
scleroderma reference populations illustrated. Testing will be performed in
the context of 3-4 real patient case scenarios; testing will be recorded (audio
and video) and may be conducted over Zoom screen sharing with a study
team member if clinic closures are prolonged with the COVID-19 pandemic.
The cases will be selected to reflect typical issues arising the scleroderma
center clinic – a) whether immunosuppressive therapy needs to be initiated or
changed to treat one or more organ systems of involvement and b) whether
more extensive and potentially invasive testing is needed to assess for sclero-
derma complications. Providers will be asked to assess each case using two
methods – standard of care (e.g. examining the Epic EMR) and the visual-
ization tool. Half of the providers will be asked to do the EMR assessments
87
first, and half will be asked to use the visualization tool first. Providers will
be instructed to verbally describe their thought process during the session.
Throughout this process, we will record the time spent looking for distinct
data elements, the types and numbers of tests or clinical features examined
or not, and the number of clicks used. Total time examining the case before
arriving at a decision will be noted. Providers will be asked about which deci-
sion they made and the level of confidence they have that they made a correct
decision. Providers will also fill out a System Usability Scale questionnaire
(Brooke, 1995, see Appendix B.1) to assess the value of the data visualization
tool. Qualitative feedback will be solicited from providers at the end of the
session to understand potential areas for improvement, alternative design
ideas, whether any data elements were unclear, and user perception of task
ease/difficulty. A study team member will take observation notes during
the exercise to capture these factors and the sequence of tasks performed by
providers.
After deployment of the visualization for at least 3 months, we will assess
whether the providers are better able to see concerning trends or new patterns
of disease evolution (i.e. higher rate of skin change coincides with worsening
cardiac disease) than prior to use of the tool. Additionally, we will assess
if this tool has altered the provider’s work flow or practice habits in any
way. Furthermore, we will assess whether the presentation of the data in this
manner contributed to the generation of new scientific questions, and if so,
what observations led to the generation of the new ideas. These assessments
will occur twice over the duration of the yearlong study.
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For patient participants, we will perform a qualitative evaluation using
semi-structured interviews to gain early feedback on a patient’s perception
of seeing his/her longitudinal trajectory illustrated. This may be conducted
over Zoom in the setting of COVID-19. In particular we will solicit feedback
on how patients feel about seeing their data illustrated relative to aggregate
cohort data, and how they understand and interpret the data in the tool. We
will recruit up to 15 patients in this phase of the study. Feedback gained may
inform whether modifications need to be made to the visualization tool and
whether any additional factors need to be studied in Phase 2 detailed below.
See Appendix B.2 for the questionnaires that will be used in Phase 1.
Phase 2 - The study population for this phase will be scleroderma center
patient participants. Through our approved registry IRB, cohort patients will
already have completed the Combined Outcome Measure for Risk Communi-
cation and Treatment Decision Making Effectiveness (COMRADE) question-
naire (Edwards et al., 2003, see Appendix B.3); this patient-reported outcome
measure assesses how patients feel about transmission of information to make
medical decisions, satisfaction with decision making, and decisional regret.
Through this new proposal, patients will be consented to participate in
study of the visualization tool. Patients will be randomized 1:1 to deployment
of the visualization tool – that is, half will be exposed to the visualization and
half will not. This randomization will enable us to determine whether the
visualization tool improves patients’ understanding of their disease and sense
of shared decision making. After the clinical visit, patients will be asked to
rate their understanding of their disease state and complete the COMRADE
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questionnaire. Patients who are randomized to the visualization tool will
complete an additional questionnaire (see Appendix B.4) specific to the tool’s
usability. Separate study visits are not required for this phase of the study. All
data will be collected in the context of routine clinical care or telemedicine
visits.
4.3.5.2 Statistical analysis
In this section, we lay out the statistical analysis plan using data captured
from the Phase 2 questionnaire (see Appendix B.4) and estimate adequate
sample size. Our primary goal is to compare the satisfaction scores for two
patient groups: with visualization assistance (VA) and without VA. Within
each provider, an equal number of patients will be randomized into the two
groups.
We plan to fit a series of linear random effects models, where the outcome
variable is a satisfaction score standardized to have mean 0 and variance
1. For the most basic model, we include a patient group indicator as the
fixed effects, and provider indicator as the random effects. By fitting the
random effects model, we control for the correlation of observations within a
provider. As the secondary analysis, we will additionally control for baseline
covariates including patient’s age, years since onset, years since their first
visit at the clinic, and disease severity score. We will also estimate treatment
effects separately for each subgroup of patients defined by the covariates. By
comparing the estimated treatments to that of the base model and also by
comparing the treatment effects across the subgroups, we can check if the
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selected covariates confound or modify the treatment effects.
After estimating the standard deviation (σ) of the outcome variables from
the model, we can determine more precisely the number of patients required
to achieve a given power to detect a group mean difference or the effect
size. To achieve a power (β) of at least 0.8 and α = 0.05, we require around
64 patients in each group to detect an effect size of 0.5 standard deviations
assuming σ=1. Effect size of 0.3 requires 175 patients per group, and effect
size of 0.7 requires 33 patients per group with the same conditions. With our
design of 100 patients total, we have 80% power to detect the difference in the
satisfaction scores of the standard of care and visualization tool.
4.4 Discussion
This visualization and analysis tool is designed to improve both provider and
patient satisfaction, improve clinical decision making, and reduce decisional
regret for patients with this complex rheumatic disease. We also present a
way of testing the utility of our visualization tool to improve shared medical
decision making and patients’ understanding of their disease state. In addition,
we seek to test whether the tool improves the efficiency of clinical care.
Development of the visualization tool and testing its utility required col-
lective effort of clinicians, statisticians, Johns Hopkins TIC staff, and human
factors specialists. While we plan to carry out all components of Phase 1
evaluation by the end of 2020, continuous efforts are made to improve the
VA. In particular, we are in the process of testing and calibrating the tools that
estimate and project health trajectories in order for them to be embedded in
91
the Epic Patient Tool and eventually be useful in clinic.
One of the major goals for statisticians is to estimate the medication effect
based on patients’ health trajectory and medication history. We are currently
building a Bayesian causal effects model that yields predictions about the
likely effects of selected interventions, for a specific patient, or in a population
of patients. Embedding patients’ future projections and the changes thereof
in trajectory for different combinations of medications is the final goal of this
project.
Another long-term goal of this project is disseminating this tool as a re-
source beyond Johns Hopkins Scleroderma Center. The visualization app and
statistical models used in this study allow flexible parameterization and can be
applied to display clinical data and model health trajectories for other complex
diseases. In particular, we saw an opportunity to leverage the resources of the
Hopkins inHealth initiative to build a framework that could be scaled up and




The works presented in this thesis comprise methods to better utilize available
clinical data to improve clinical care for scleroderma. In our application, a
patient’s health state is reflected in multiple irregularly spaced longitudinal
measures and events. In some instances, the events of interest represent
threshold crossings of those same longitudinal measures. A first objective
was to estimate smooth individual and population health trajectories across
different organ systems using noisy and, for many individuals, sparse data.
We estimated the trajectories by selecting and estimating multivariate Bayesian
hierarchical models that accommodate the nested structure of the observed
outcome variables and multiple clinically-relevant predictor variables. From
the model, we furthered our understanding of the complexity of the disease by
studying estimated disease progression in multidimension space for clinically
defined subpopulations as well as the estimated correlations across measures
and time.
To achieve the clinical aim, we confronted the question: in cases like
scleroderma, does fitting a more complex multivariate hierarchical model
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("combined model") produce substantially more efficient estimates compared
to fitting a set of "separated models", that is, separate univariate models for
each measure. In regression analysis, this question was raised by Zellner (Zell-
ner, 1962) who coined the term "seemingly unrelated regression" equations
or SUR. He showed that the coefficient estimation using the GLS (Aitken,
1934) is asymptotically more efficient compared to the OLS, and that the ef-
ficiency increases as the error terms from different equations become more
cross-correlated and as the predictor variables in different equations become
less correlated. The OLS estimates are only as efficient as the GLS, when
each equations system representing the relationship between each outcome
variable and its set of predictor variables are uncorrelated in random error
terms across outcomes. But multivariate linear mixed models, which addi-
tionally involves random effects defined through time across all outcomes,
are not separable into individual equation systems without efficiency loss as
can happen in SUR where the equations are connected only through random
error terms. With mixed effect models, there is also an additional question:
how does the seemingly unrelated approach (separated models) do for Bayes
estimates of individual slopes? All previous work was about the fixed effects.
We derived a set of generalizable formulae to compare the relative efficiency
of population and individual-level estimates from the fully efficient combined
model and the simpler separated models. The relative performance of the
combined model depended on the amount of the available data and the degree
of correlation between the measure of interest and the other measures. For
estimating the fixed effects in the scleroderma application, both models were
provided with rich data, hence we observe minimal gain in reduced variance
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by fitting the combined model. On the other hand, there are sizeable gains
in estimating random effects for those individual’s for whom the relative
number of observations in the measure of interest is smaller than those in
other correlated measures. The degree of efficiency gain increases with the
degree of correlation.
We found that the reduction in MSE mostly results from reduced bias. For
individuals who have only a few data points available for a given measure,
the data for the measure alone cannot accurately reflect the underlying disease
state of the individual. Hence, fitting the separated models results in greater
shrinkage towards the measure-specific mean and results in larger bias. The
bias is reduced when fitting the combined model, where the random effects
estimator borrows strength from data-rich measures and yields more efficient
estimates.
Estimating the risk of future clinical events is another clinical priority, so
we built prediction algorithms that fully utilize the information in patients’
past trajectories. Logistic regression models and machine learning algorithms
such as ensemble methods using decision trees are frequently used to build
prediction models where the outcome of interest is a binary event. However,
it is difficult to incorporate the multidimensional trajectory information in
a disease like scleroderma for such models. Also, there is a huge loss of
information by transforming a continuous outcome into a binary variable.
Hence, we used the framework developed to estimate individual trajectory
by jointly modeling multiple markers and extended the models to predicting
patients’ risk of having critical events in the near future.
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We implemented the prediction calculations by developing a cross-validated,
sequential prediction algorithm (CVSP) for multivariate longitudinal data
(MLD). The algorithm sequentially produces the most likely trajectory and
the risk of clinical events as additional data points are observed for a patient.
The predictions are made without refitting the model to incorporate new
observations for a patient using K-fold cross-validation method. We divide
patients into k folds of data. To obtain predictions for a patient in the kth
fold, we produce estimates of the random error and random effects covari-
ance matrices leaving out the kth fold. In this way the estimated matrices by
construction are independent of the left out data. We then use the fixed and
random effect estimates which are functionals of the estimated covariance
matrices to sequentially estimate a patient’s risk of events given only the
past data. The CVSP for MLD produces predictions of six clinical outcomes
of interest with substantially higher precision as compared to the empirical
prediction methods using logistic regression models. Moreover, we showed
that CVSP increases in precision as more data are observed for a given patient
and that, even with no observations for an individual’s measure, CVSP yields
predictions with considerable precision. The result implies that we can still
rely on the estimation of the risk of an event, when there is no available data
for the corresponding measure, because our model borrows strength from
the patient’s data in other measures and also from other patients with similar
characteristics. It should be noted that the events used in our application are
directly determined by longitudinal measures used in the model. Modeling
for events that are not functions of the longitudinal measures, i.e. death,
requires additional modeling work.
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In Chapter 4, we presented an interactive visualization application for
physicians and/or patients that displays a patient’s longitudinal data, esti-
mates of their prior trajectory with its uncertainty, and prediction of future
measures and the associated risks of critical events. The tool is designed to
automatically aggregate clinical phenotype and longitudinal data in a snap-
shot view to facilitate evidence-based practice and shared decision making for
physicians and help patients understand their disease status better. There are
multiple challenges in order for the visualization tool to be used in the clinic.
First, we need to test the usability of the tool, demonstrating improved satisfac-
tion of both physicians and patients. We designed the qualitative studies and
trials in two phases and throughout will continue to improve the tool based
on the feedback we gather from the questionnaires. Currently, the Epic-based
tool does not include the estimation and prediction tools mentioned above.
One of the major future goals of this project is to further update the tool with
the predictions and design trials to test its usability for its broader use.
The methods developed in this thesis have limitations despite our effort
to give them broad domains of application. Each limitation represents an
opportunity for further work. First, we rely upon the multivariate Gaussian
distribution in order to derive estimates and predictions about an individual’s
trajectory. We accommodate non-Gaussian marginals by quantile normaliza-
tion and further check for violations of multivariate Gaussian random effects
and residuals. Nevertheless, the Gaussian assumption makes the methods
sensitive to outliers in either the random effects or errors. Model checking
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is therefore essential with current version. We plan to broaden the applica-
tion by allowing the random effects and errors to follow a t-distribution with
smaller degrees of freedom rather than the Gaussian to admit longer-tailed
distributions.
Second, our clinician colleagues believe strongly that there are subsets
of patients over and above those represented by fixed effects such as auto-
antibody type. To accommodate this possibility, we can extend the model
by allowing the random effects distributions to be a mixture of multiple
Gaussians with different means. This approach has been used in "growth
curve models" in the social sciences literature (Muthen, 2001).
Finally, we have made progress toward answering two of our motivating
clinical questions asked by patients: (1) what is my current disease state; (2)
what is my trajectory - where can I expect to be in the near future? The third
question is: of the treatments currently available, which one is best for me
going forward? The models proposed here have extensions to incorporate the
causal question about treatments. The fixed effects regressions can include
treatment indicators to quantify observed difference between treatment sub-
groups. The prior distributions for the treatment effects can incorporate the
results of relevant clinical trials. Heterogeneity among patients in the effects
of treatments can be included using random effects. However, treatments
are rarely assigned through randomization in clinical practice. Hence, it is
necessary to model the treatment assignment as another outcome in the mul-
tivariate model. With colleagues, we currently are working toward having
useful answers for the third question and to communicate them to patients
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and clinicians in the apps developed here and test them in the subsequent





A.1 Mean Squared Error and bias-variance decom-
position
The mean squared error (MSE) of an estimator θ ∈ Rd is defined as




(θ̂ j − θj)2) = Tr(Var(θ̂)) + ||Bias(θ̂)||2
where Bias(θ̂) = E(θ̂)− θ. Note that Var(θ̂) is the covariance matrix of
θ̂ and its trace is ∑dj=1 Var(θ̂ j). Since MSE(θ̂, θ) = ∑
d
j=1 E((θ̂ j − θj)2), it is
sufficient to show E((θ̂ − θ)2) = Var(θ̂) + Bias2(θ̂) to prove the above result.
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E((θ̂ − θ)2) = E((θ̂ − E(θ̂)) + (E(θ̂)− θ))2 = E{(θ̂ − E(θ̂))2 + (E(θ̂)− θ)2
+ 2(θ̂ − E(θ̂))(E(θ̂)− θ)}
= E(θ̂ − E(θ̂))2 + (E(θ̂)− θ)2 + 2(E(θ̂)− E(θ̂))(E(θ̂)− θ)}
= E(θ̂ − E(θ̂))2 + (E(θ̂)− θ)2
= Var(θ̂) + Bias2(θ̂)
Under our assumptions, E(Y) = Xβ and var(Y) = VC, the fixed effect






MSE(β̂S, β) = Tr(var(β̂S)) = Tr((X
TWSX)−1XTWSvar(Y)WSX(XTWSX)−1)
= Tr((XTWSX)−1XTWSVCWSX(XTWSX)−1)
MSE(β̂C, β) = Tr(var(β̂C)) = Tr((X
TWCX)−1)
MSE for random effects b̂Si and b̂Ci can be decomposed into variance
and bias components. Note that under our assumptions, var(ϵi) = ΣCi and
var(bi) = DC. For the separated model,
Ebi{MSE(b̂Si, bi)} = Ebi{Tr(varb̂Si|bi(b̂Si|bi))}+ Ebi{||Bias(b̂Si)||
2}
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where the variance component is
Ebi{Tr(varyi|bi(b̂Si|bi))} = Tr{DSZ
T
i (WSi − WSiXi(XTWSX)−1XTi WSi)ΣCi





since varb̂Si|bi(b̂Si|bi) = varb̂Si|bi(DSZ
T
i WSi(yi − Xi β̂S)|bi)
= varb̂Si|bi(DSZ
T

































The bias component is estimated as following
Ebi{||Bias(b̂Si)||
2} = Ebi{||(E(b̂Si|bi)− bi)||
2} = Ebi{Tr((E(b̂Si|bi)− bi)(E(b̂Si|bi)− bi)
T)}
= Tr{(DSZTi (WSi − WSiXi(XTWSX)−1XTi WSi)Zi − I)Ebi(bib
T
i )
×(DSZTi (WSi − WSiXi(XTWSX)−1XTi WSi)Zi − I)T}
= Tr{(DSZTi (WSi − WSiXi(XTWSX)−1XTi WSi)Zi − I)DC
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i WSi(yi − Xi β̂S)|bi)
= Eb̂Si|bi(DSZ
T



















= DSZTi WSi{(I − Xi(XTWSX)−1XTi WSi)Zibi





= DSZTi WSi{(I − Xi(XTWSX)−1XTi WSi)Zibi





= DSZTi WSi{(I − Xi(XTWSX)−1XTi WSi)Zibi
Similarly, for the combined model
Ebi{MSE(b̂Ci, bi)} = Ebi{Tr(varb̂Ci|bi(b̂Ci|bi))}+ Ebi{||Bias(b̂Ci)||
2}
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where the variance component is
Ebi{Tr(varyi|bi(b̂Ci|bi))} = Tr{DCZ
T
i (WCi − WCiXi(XTWCX)−1XTi WCi)ΣCi





since varb̂Ci|bi(b̂Ci|bi) = varb̂Ci|bi(DCZ
T
i WCi(yi − Xi β̂C)|bi)
= varb̂Ci|bi(DCZ
T



















The bias component is
Ebi{||Bias(b̂Ci)||
2} = Ebi{Tr((E(b̂Ci|bi)− bi)(E(b̂Ci|bi)− bi)
T)}
= Tr{(DCZTi (WCi − WCiXi(XTWCX)−1XTi WCi)Zi − I)DC
×(DCZTi (WCi − WCiXi(XTWCX)−1XTi WCi)Zi − I)T}
since Eb̂Ci|bi(b̂Ci|bi) = Eb̂Ci|bi(DCZ
T
i WCi(yi − Xi β̂C)|bi)
= DCZTi WCi{(I − Xi(XTWCX)−1XTi WCi)Zibi.
Lastly, MSE for ŷSi = Xi β̂S + Zib̂i = Xi β̂S + ZiDSZ
T
i WSi(yi − Xi β̂S) can be
written as
Ebi{MSE(ŷSi, E(ŷi|bi))} = Ebi{Tr(varŷSi|bi(ŷSi|bi))}+ Ebi{||Bias(ŷSi)||
2}
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EŷSi|bi(ŷSi|bi) and varŷSi|bi(ŷSi|bi) is derived where
MSi = (Xi − ZiDSZTi WSiXi)(XTWSX)−1
EŷSi|bi(ŷSi|bi) = EŷSi|bi(Xi β̂S + ZiDSZ
T










i WSiyi + ZiDSZ
T





= MSiXTi WSi(Xiβ + Zibi) + ZiDSZ
T





= Xiβ + {MSiXTi + ZiDSZTi }WSiZibi
varŷSi|bi(ŷSi|bi) = varŷSi|bi{MSiX
T
i WSiyi + ZiDSZ
T















































i }WSi − I)ZibibTi Zi({MSiXTi +ZiDSZTi }WSi − I)T})
= Tr(({MSiXTi + ZiDSZTi }WSi − I)ZiDCiZi({MSiXTi + ZiDSZTi }WSi − I)T)
MSE for ŷCi = Xi β̂C + ZiDCZ
T
i WCi(yi − Xi β̂C) is
Ebi{MSE(ŷCi, E(ŷi|bi))} = Ebi{Tr(varŷCi|bi(ŷCi|bi))}+ Ebi{||Bias(ŷCi)||
2}
Letting MCi = (Xi − ZiDCZTi WCiXi)(XTWCX)−1,
EŷSi|bi(ŷCi|bi) = EŷCi|bi(Xi β̂C + ZiDCZ
T










i WCiyi + ZiDCZ
T





= MCiXTi WCi(Xiβ + Zibi) + ZiDCZ
T





= Xiβ + {MCiXTi + ZiDCZTi }WCiZibi
varŷCi|bi(ŷCi|bi) = varŷCi|bi{MCiX
T
i WCiyi + ZiDCZ
T















































i }WCi − I)ZibibTi Zi({MCiXTi +ZiDCZTi }WCi − I)T})
= Tr(({MCiXTi + ZiDCZTi }WCi − I)ZiDCiZi({MCiXTi + ZiDCZTi }WCi − I)T)
A.2 Correlation matrices with varying degrees of
correlation across patient-specific trends
pFVC pDLCO EF RVSP mRSS
pFVC 1.00 0.64 0.10 0.37 0.27
pDLCO 0.64 1.00 -0.10 0.40 0.20
EF 0.10 -0.10 1.00 0.10 -0.10
RVSP 0.37 0.40 0.10 1.00 0.13
mRSS 0.27 0.20 -0.10 0.13 1.00
Table A.1: Correlation across random slope components from C
′
0.1
pFVC pDLCO EF RVSP mRSS
pFVC 1.00 0.64 0.20 0.37 0.27
pDLCO 0.64 1.00 -0.20 0.40 0.20
EF 0.20 -0.20 1.00 0.20 -0.20
RVSP 0.37 0.40 0.20 1.00 0.13
mRSS 0.27 0.20 -0.20 0.13 1.00




pFVC pDLCO EF RVSP mRSS
pFVC 1.00 0.62 0.28 0.38 0.26
pDLCO 0.62 1.00 -0.28 0.39 0.21
EF 0.28 -0.28 1.00 0.29 -0.28
RVSP 0.38 0.39 0.29 1.00 0.12
mRSS 0.26 0.21 -0.28 0.12 1.00







B.1 System Usability Scale questionnaire
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B.3 The COMRADE questionnaire
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Graduate Research Assistant 
Johns Hopkins University Department of Biostatistics, Baltimore, Maryland              November 2014 to present 
  
       Survival, Longitudinal and Multivariate Models for Health Monitoring    
• Designed a Bayesian method for predicting Scleroderma patients’ disease state or trajectory given patterns observed in 
multivariate symptom measures 
• Compared and measured relative merits of the model fully utilizing information in multiple longitudinal markers to 
those of marker-specific models 
Development of a Predictive Model of Left Ventricular Failure in Scleroderma                       
• Identified patients at high risk of left ventricular failure using demographics, clinical features, autoantibody status 
• Developed a prediction tool for individual patients’ anticipated ejection fraction values at any given time using time-
varying ejection fraction data as well as baseline variables   
Methods for Evaluating Health Programs with Pre-existing Data                                    
• Built a causal model of child mortality in sub-Saharan African Countries utilizing pre-existing household surveys  
• Evaluated district-wise impact of a health program on mortality using mixed effects hierarchical logistic regression 
models 
Assessing Impact of Sleep Stages and Duration on Mortality  
• Explored various components of sleep that affect survival for individuals using polysomnography data 
 
Neuroimaging projects using MRI and fMRI images                
• Investigated methods of measuring reproducibility of correlation matrices of independent components in fMRI 
• Performed longitudinal investigation of multiple sclerosis lesion intensity trajectories in MRI 




Co-instructor                            
Advanced Biostatistics Topics Seminar Course: Bayesian Hierarchical Models for Individualized Health 
Scott L. Zeger and Ji Soo Kim          September 2019 
 
• Designed and taught course materials introducing statistical foundation of Bayesian hierarchical models and 
computational approaches to fit models for multivariate longitudinal data and make inference on their results  
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• 140.656: Multilevel Statistical Models in Public Health (2020 – Lead TA)  
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• 140.622-4: Statistical Methods in Public Health II, III & IV (2018) 
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• Built Bayesian hierarchical models to measure and compare differences in practices across multiple health providers 
using multiple binary clinical measures as outcome and made visualizations to help interpret model estimates 
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• Ji Soo Kim, Ami Shah, Laura Hummers, Scott L. Zeger, “Modeling Repeated Multivariate Data to Estimate 
Individuals’ Trajectories with Application to Scleroderma.”  
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Scleroderma Data Visualization Tool (R Shiny App)         
• Interactive tool for visualizing patient data and predictions to improve clinicians’ assessment of an individual patient’s 
health state and trajectory 
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• Software for visualizing feature importance and feature effect of machine learning algorithms based upon the 
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